WO2022204793A1 - Binding agents targeting tumors and/or immune cells - Google Patents

Binding agents targeting tumors and/or immune cells Download PDF

Info

Publication number
WO2022204793A1
WO2022204793A1 PCT/CA2022/050442 CA2022050442W WO2022204793A1 WO 2022204793 A1 WO2022204793 A1 WO 2022204793A1 CA 2022050442 W CA2022050442 W CA 2022050442W WO 2022204793 A1 WO2022204793 A1 WO 2022204793A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid sequence
seq
binding agent
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2022/050442
Other languages
English (en)
French (fr)
Inventor
Shugang YAO
Richard WARGACHUCK
Yun CUI
Wenyang HOU
Jacynthe TOULOUSE
Elijus UNDZYS
Anna KAZANETS
Liying GONG
Milica KRSTIC
Xiaowei Wang
Hiba Zahreddine
Luis DA CRUZ
David S. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kisoji Biotechnology Inc
Original Assignee
Kisoji Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kisoji Biotechnology Inc filed Critical Kisoji Biotechnology Inc
Priority to CA3174330A priority Critical patent/CA3174330A1/en
Priority to EP22778240.6A priority patent/EP4314076A4/en
Priority to US18/283,579 priority patent/US20240166739A1/en
Priority to CN202280025997.9A priority patent/CN117157322A/zh
Priority to JP2023560694A priority patent/JP2024512741A/ja
Priority to ARP220100796A priority patent/AR125264A1/es
Priority to TW111112543A priority patent/TW202304993A/zh
Publication of WO2022204793A1 publication Critical patent/WO2022204793A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • the present disclosure generally relates to binding agents that are capable of targeting tumor cells and/or immune cells.
  • the binding agents of the present disclosure comprise one or more antigen binding domains of VHH antibodies which are capable of binding to DR2, to PD-1 and/or to CD47.
  • the binding agents of the present disclosure may be in the form of monomers or multimers and may be monospecific or multispecific.
  • HCAbs functional homodimeric heavy chain only antibodies
  • the heavy chains of HCAbs lack the first constant domain (CHI) and differs from classical antibodies by only a few amino acids substitutions normally involved in light chain pairing (Muyldermans et al., 1994; Vu et al., 1997). These substitutions (Val37Phe/Tyr, Gly44Glu, Leu45Arg, and Trp47Gly) are present in framework region 2 (FR2).
  • FR2 framework region 2
  • the antigen-binding fragment of HCAbs is referred to as, VHH or nanobody®.
  • VHHs have a molecular weight of around 15 kDa which makes them amenable to applications that require enhanced tissue penetration or rapid clearance, such as radioisotope-based imaging.
  • the VHH half-life usually needs to be increased so as to minimize renal clearance and optimize therapeutic efficacy (De Vlieger et al., Antibodies 8(1), 1-22, 2019).
  • methods to increase VHH half-life such as PEGylation, N-glycosylation, HSA or other carrier protein fusions have been exploited, such construct can introduce immunogenicity or have limited success.
  • VHHs have been exploited as building blocks to make bispecific and multispecific antibodies.
  • bivalent constructs have been shown to be have increased avidity or affinity compared to the monovalent form (Conrath et al., 2001; Coppieters et al., 2006; Hmila et al., 2008; Simmons et al., 2006 and Hultberg et al., 2011, Jahnichen et al. (2010), Fridy et al., 2014).
  • VHH-based therapeutics are currently in late investigational stage or have been approved by FDA. These include the bivalent monospecific antibody Caplacizumab against antigen vWF approved for Thrombotic thrombocytopenic purpura (Duggan, 2018).
  • a Trivalent nanobody complex, ALX-0171 against RSV is at late-stage development for Respiratory syncytial virus infection (Detallea et al., 2015).
  • ALX-0061 is a monovalent against antigen IL-6R but attached with HSA nanobody to extend half-life and is at clinical development stage for RA and SLE indications (Van Roy et al., 2015).
  • the investigational drug ALX-0761 contains three nanobodies against antigens IL-17A, IL-17F and HAS and is being developed for Psoriasis (Svecova et., 2019).
  • Anti-RANKL, ALX-0141 is a bivalent for antigen RANKL and attached to HSA to extend half-life (Schoen et al., 2013).
  • Ozoralizumab is bivalent nanobody against antigen TNFa and attached to HSA to extend half-life (Fleischmann et al., 2012).
  • the Applicant has developed novel binding agents that targets tumors cells and/or immune cells that contains one or more antigen binding domains.
  • the present disclosure generally relates to binding agents that are capable, amongst other things, of targeting tumor cells and/or immune cells.
  • the binding agents of the present disclosure are capable of binding to DR2, to PD-1 and/or to CD47. In other embodiments of the present disclosure, the binding agents may bind to cells expressing DR2, to cells expressing PD-1 and/or to cells expressing CD47.
  • the cells expressing DR2 comprise tumor cells.
  • the cells expressing PD-1 comprises immune cells.
  • the cells expressing CD47 comprises immune cells or tumor cells.
  • the binding agent may comprise an antigen binding domain capable of binding to DR2 or to cells expressing DR2, an antigen binding domain capable of binding to PD-1 or to cells expressing PD-1 and/or an antigen binding domain capable of binding to CD47 or to cells expressing CD47.
  • the binding agent may also comprise additional antigen binding domains.
  • the antigen binding domain capable of binding to DR2 or to cells expressing DR2 is an antigen binding domain 1 (ABD1) as described herein. In some embodiments, the antigen binding domain capable of binding to DR2 or to cells expressing DR2 is not limited to antigen binding domain 1 (ABD1).
  • the binding agent may comprise at least one antigen binding domain 1 (ABD1).
  • the binding agent may comprise at least one antigen binding domain
  • ABS1 antigen binding domain 1
  • the binding agent may comprise at least one antigen binding domain 1 (ABD1) and may also bind to immune cells. Accordingly, in some embodiments, the binding agent comprises comprise at least one antigen binding domain 1 (ABD1) and at least one antigen binding domain that binds to immune cells.
  • the antigen binding domain capable of binding to PD-1 or to cells expressing PD-1 is an antigen binding domain 2 (ABD2) as described herein. In some embodiments, the antigen binding domain capable of binding to PD-1 or to cells expressing PD-1 is not limited to antigen binding domain 2 (ABD2).
  • the binding agent may comprise at least one antigen binding domain 2 (ABD2).
  • the binding agent may comprise at least one antigen binding domain
  • ABS2 antigen binding domain
  • the binding agent may comprise at least one antigen binding domain 2 (ABD2) and may also bind to tumor cells. Accordingly, in some embodiments, the binding agent comprises at least one antigen binding domain 2 (ABD2) and at least one antigen binding domain that binds tumor cells.
  • the antigen binding domain capable of binding to CD47 or to cells expressing CD47 is an antigen binding domain 3 (ABD3) as described herein. In some embodiments, the antigen binding domain capable of binding to CD47 or to cells expressing CD47 is not limited to ABD3.
  • the binding agent may comprise at least one antigen binding domain 3 (ABD3).
  • the binding agent may comprise at least one antigen binding domain 3 (ABD3) and at least one other antigen binding domain.
  • the binding agent may comprise at least one antigen binding domain 3 (ABD3) and may also bind to tumor cells. Accordingly, in some embodiments, the binding agent comprises at least one antigen binding domain 3 (ABD3) and at least one antigen binding domain that binds to tumor cells In other instances, the binding agent may comprise at least one antigen binding domain 3 (ABD3) and may also bind to immune cells. In some embodiments, the binding agent comprises at least one antigen binding domain 3 (ABD3) and at least one antigen binding domain that binds to immune cells.
  • the binding agent is capable of binding to DR2 and to PD-1. Accordingly, in some embodiments, the binding agent comprises at least one antigen binding domain that binds to DR2 and at least one antigen binding domain that binds to PD-1.
  • the binding agent is capable of binding to DR2 and to CD47. Accordingly, in some embodiments, the binding agent comprises at least one antigen binding domain that binds to DR2 and at least one antigen binding domain that binds to CD47.
  • the binding agent is capable of binding to DR2, PD-1 and to CD47. Accordingly, in some embodiments, the binding agent comprises at least one antigen binding domain that binds to DR2, at least one antigen binding domain that binds to PD-1 and at least one antigen binding domain that binds to CD47.
  • the binding agent is capable of binding to PD-1 and to CD47. Accordingly, in some embodiments, the binding agent comprises at least one antigen binding domain that binds to PD-1 and at least one antigen binding domain that binds to CD47.
  • the binding agent is capable of binding to PD-1, to CD47 and to tumor cells. Accordingly, in some embodiments, the binding agent comprises at least one antigen binding domain that binds to PD-1, at least one antigen binding domain that binds to CD47 and at least one antigen binding domain that binds to tumor cells.
  • the binding agent is capable of binding to PD-1 and to tumor cells. Accordingly, in some embodiments, the binding agent comprises at least one antigen binding domain that binds to PD-1 and at least one antigen binding domain that binds to tumor cells. In some instances, the binding agent is capable of binding to CD47 and to tumor cells. Accordingly, in some embodiments, the binding agent comprises at least one antigen binding domain that binds to CD47 and at least one antigen binding domain that binds to tumor cells.
  • the binding agent is capable of binding to CD47 and to immune cells. Accordingly, in some embodiments, the binding agent comprises at least one antigen binding domain that binds to CD47 and at least one antigen binding domain that binds to immune cells.
  • the binding agent comprises one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1).
  • ABS1 antigen binding domain 1
  • the binding agent comprises one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 2 (ABD2).
  • ABS2 antigen binding domain 2
  • the binding agent comprises one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 3 (ABD3).
  • ABS3 antigen binding domain 3
  • the binding agent comprises one or more antigen binding domains, wherein at least one of the antigen binding domains is selected from: an antigen binding domain 1 (ABD1), an antigen binding domain 2 (ABD2) or, an antigen binding domain 3 (ABD3).
  • the binding agent may comprise an antigen binding domain that targets epitopes other than those covered by ABD1, ABD2 and ABD3.
  • the binding agent may thus comprise an antigen binding domain that has the same or different specificity as that of ABD1, ABD2 and/or ABD3.
  • the binding agent may comprise more than one antigen binding domains.
  • the binding agent may comprise comprises two antigen binding domains or more, three antigen binding domains or more, four antigen binding domains or more, five antigen binding domains or more, six antigen binding domains or more, seven antigen binding domains or more, eight antigen binding domains or more, nine antigen binding domains or more, ten antigen binding domains or more.
  • the binding agent may comprise between one and twelve antigen binding domains.
  • the binding agents of the present disclosure may be monospecific.
  • the binding agents of the present disclosure may be multispecific.
  • the binding agents of the present disclosure may be monovalent.
  • the binding agents of the present disclosure may be multivalent.
  • the binding agents of the present disclosure may be in the form of a monomer.
  • the binding agents of the present disclosure may be in the form of a dimer or higher order form such as trimer, four-mer, five-mer and the like (e.g., multimer).
  • the antigen binding domain of the binding agent originates from a heavy chain antibody.
  • the heavy chain antibodies may be obtained by immunization of camelids or transgenic animals.
  • the binding agent comprises at least one antigen binding domain that binds to DR2 and that comprises complementarity determining regions set forth herein.
  • the binding agent comprises at least one antigen binding domain that binds to PD-1 and that comprises complementarity determining regions set forth herein.
  • the binding agent comprises at least one antigen binding domain that binds to CD47 and that comprises complementarity determining regions set forth herein.
  • the antigen binding domains are on one or more polypeptide chains.
  • the antigen binding domains antigen are on same polypeptide chain.
  • the binding agent comprises a single polypeptide chain.
  • the binding agent comprises two polypeptide chains. Accordingly, the binding agent may be in the form of a dimer.
  • the binding agent comprises more than two polypeptide chains, such as three polypeptide chains or more, four polypeptide chains or more, five polypeptide chains or more, six polypeptide chains or more, seven polypeptide chains or more, eight polypeptide chains or more, nine polypeptide chains or more, ten polypeptide chains or more.
  • the binding agent may be in the form of a multimer.
  • a binding agent that comprises three polypeptide chains is referred herein as a trimer
  • a binding agent that comprises four polypeptide chains is referred herein as a four-mer, and the like.
  • the binding agent comprises at least two polypeptide chains that are capable of assembling to form a dimer and wherein each polypeptide chain comprises one or more antigen binding domains.
  • the two polypeptide chains are capable of assembling to form a dimer and each polypeptide chain comprises different antigen binding domains.
  • the two polypeptide chains are capable of assembling to form a dimer and each polypeptide chain comprises the same antigen binding domains.
  • each polypeptide chain comprises identical antigen binding domain
  • each polypeptide chain comprises identical antigen binding domain
  • each polypeptide chain comprises identical antigen binding domain
  • the binding agent comprises at least two polypeptide chains that assemble to form a dimer and each polypeptide chain comprises identical antigen binding domain 1 (ABD1) and identical antigen binding domain 2 (ABD2).
  • the binding agent comprises at least two polypeptide chains that assemble to form a dimer and each polypeptide chain comprises identical antigen binding domain 1 (ABD1) and identical antigen binding domain 3 (ABD3).
  • the binding agent comprises at least two polypeptide chains that assemble to form a dimer and each polypeptide chain comprises identical antigen binding domain 2 (ABD2) and identical antigen binding domain 3 (ABD3).
  • the binding agent comprises at least two polypeptide chains that assemble to form a dimer and each polypeptide chain comprises identical antigen binding domain 1 (ABD1), identical antigen binding domain 2 (ABD2) and identical antigen binding domain 2 (ABD3).
  • the antigen binding domain 1 (ABD1), antigen binding domain 2 (ABD2) and antigen binding domain 2 (ABD3) may occupy the same position on each of the two polypeptide chains.
  • the antigen binding domain 1 (ABD1), antigen binding domain 2 (ABD2) and antigen binding domain 2 (ABD3) may occupy different positions on each of the two polypeptide chains.
  • each polypeptide chains of the binding agent are the same.
  • each polypeptide chains of the binding agent are different.
  • the two polypeptide chains are capable of assembling to form a homodimer.
  • the two polypeptide chains are capable of assembling to form a heterodimer.
  • antigen binding domains are separated by an amino acid sequence.
  • the amino acid sequence is a linker.
  • Binding agents of the present disclosure encompass for example the antigen binding domains disclosed herein, single polypeptide chain disclosed herein, dimers of the polypeptide chains disclosed herein or multimers of the polypeptide chains disclosed herein.
  • binding agents of the present disclosure may have a format of an antibody and antigen binding fragment thereof, an antibody -like molecule (Fc-, CH3- fusions and the like), a fusion with protein scaffolds, immune cell modulating agents and the like.
  • the binding agents of the present disclosure may have a format as disclosed in PCT/CA2020/051753 filed on December 18, 2020 (the entire content of which is incorporated herein by reference) as formula la, formula lb, formula Ic, formula II, formula III, formula IV, formula V, formula VI, formula VII or formula VIII and the like or formula I, formula II, formula III, formula Ilia and formula Illb, formula IV, formula V, formula VI, formula VII or formula VIII disclosed herein.
  • the binding agents are composed of polypeptide chains comprising one or more antigen binding domains and a dimerization domain allowing at least two polypeptide chains to form dimers.
  • the binding agent of the present disclosure may comprise one or more polypeptide chains each independently comprising in a N- to C-terminal fashion an amino acid sequence of formula I:
  • n 0, 1, 2 or an integer greater than 2;
  • n 0, 1, 2 or an integer greater than 2;
  • Ab a , Ab d each represents an antigen binding domain wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1), an antigen binding domain 2 (ABD2) or an antigen binding domain 3 (ABD3);
  • X or Y are independently present or absent and comprises an amino acid sequence
  • L b , L c each independently comprises one or more linkers; and wherein DD represents a dimerization domain.
  • the polypeptide chain comprises two antigen binding domains or more, three antigen binding domains or more, four antigen binding domains or more, five antigen binding domains or more, six antigen binding domains or more, etc.
  • polypeptide chain comprises between one and twelve antigen binding domains.
  • the binding agent comprises one polypeptide chain.
  • the binding agent comprises two polypeptide chains, three polypeptide chains, four polypeptide chains, five polypeptide chains, six polypeptide chains, seven polypeptide chains, eight polypeptide chains, nine polypeptide chains, ten polypeptide chains or more than ten polypeptide chains.
  • the polypeptide chains may be covalently linked.
  • polypeptide chains may be non-covalently linked.
  • polypeptide chains may be associated via electrostatic interaction(s).
  • the [(Ab a )-(L b )] units is the same or different.
  • n 2 or an integer greater than 2
  • the [(L c )-(Ab d )] units are the same or different.
  • each Ab a is the same or different.
  • each Ab d is the same or different.
  • Ab a represents ABD1, ABD2 or ABD3.
  • Ab d represents ABD1, ABD2 or ABD3.
  • Ab d represents ABD1, ABD2 or ABD3.
  • the one or more polypeptide chain further comprises a hinge region of an antibody or antigen binding fragment thereof.
  • L b is a hinge region of an antibody or antigen binding fragment thereof.
  • the hinge region is a natural hinge region from an IgGl, IgG2, IgG3 or IgG4.
  • the hinge region is a mutated hinge region having at least 70% identity with a natural hinge region from an IgGl, IgG2, IgG3 or IgG4.
  • each of the one or more linkers independently has at least 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 amino acid residues in length.
  • each of the one or more linkers is independently a flexible linker, a helical linker, or a rigid linker.
  • the flexible linker is a GS linker.
  • the flexible linker comprises one or more units of GGGGS as described herein.
  • the rigid linker comprises multiple PA repeats as described herein.
  • the helical linker comprises one or more units of EAAAK as described herein.
  • the binding agent comprises one or more polypeptide chains wherein at least one of the polypeptide chains comprises formula II: X-(Ab ai )-(Lbi)-(DD)-(L ci )-(Abdi)-Y (formula II).
  • the binding agent comprises one or more polypeptide chains wherein at least one of the polypeptide chains comprises formula III: X-(Ab ai )-(Lbi)-(DD)-(L ci )-(Abdi)- (L C2 )-(Abd2)-Y (formula III).
  • the binding agent comprises one or more polypeptide chains wherein at least one of the polypeptide chains comprises formula IV: X-(Ab ai )-(L b2 )-(Ab a2 )-(L bi )-(DD)- (Ld)-(Abdi)-Y (formula IV).
  • the binding agent comprises one or more polypeptide chains wherein at least one of the polypeptide chains comprises formula V: X-(Ab ai )-(L b 2)-(Ab a 2)-(L bi )-(DD)- (Ld)-(Abdi)-(Lc2)-(Abd2)-Y (formula V).
  • the binding agent comprises one or more polypeptide chains wherein at least one of the polypeptide chains comprises formula VI: X-(Ab ai )-(L b 2)-(Ab a 2)-(L bi )-(DD)- (Ld)-(Abdi)-(Lc2)-(Abd2)-(Lc3)-(Abd3)-Y (formula VI).
  • the binding agent comprises one or more polypeptide chains wherein at least one of the polypeptide chains comprises formula VII: X-(Ab ai )-(Lb3)-(Ab a2 )-(Lb2)-(Ab a3 )- (Lbi)-(DD)-(Lci)-(Abdi)-(L C 2)-(Abd2)-Y (formula VII).
  • the binding agent comprises one or more polypeptide chains wherein at least one of the polypeptide chains comprises formula VIII: X-(Ab ai )-(Lb3)-(Ab a2 )-(Lb2)-(Ab a3 )- (Lbi)-(DD)-(Lci)-(Abdi)-(Lc2)-(Abd2)-(L C3 )-(Abd3)-Y (formula VIII).
  • Ab ai, Ab a2 , Ab a 3, Abdi, Abd2, or Abd 3 each independently comprises an antigen binding domain.
  • Ab ai, Ab a 2, Ab a3, Abdi, Abd2, or Abd3, each independently represents an antigen binding domain.
  • At least one of Ab ai, Ab a 2, Ab a3, Abdi, Abd2, or Abd3 is an antigen binding domain 1 (ABDI), an antigen binding domain 2 (ABD2) or an antigen binding domain 3 (ABD3).
  • At least one of Ab ai, Ab a 2, Ab a3, Abdi, Abd2, or Abd3 is not an antigen binding domain 1 (ABDI), an antigen binding domain 2 (ABD2) or an antigen binding domain 3 (ABD3).
  • Lbi comprises a linker or linkers and/or a hinge region of an antibody or antigen binding fragment thereof.
  • the hinge region is a natural hinge region as disclosed herein. In other embodiments, the hinge region is a mutated hinge region as disclosed herein.
  • L b 2, L b 3 L ci , L C 2, and L C 3 each independently comprise a linker or linkers as disclosed herein.
  • the polypeptide chain comprises the antigen binding domain ABDI as disclosed herein and an antigen binding domain that binds to an immune cell.
  • the polypeptide chain comprises the antigen binding domain ABD2 as disclosed herein and an antigen binding domain that binds to a tumor cell.
  • the polypeptide chain comprises the antigen binding domain ABD3 as disclosed herein and an antigen binding domain that binds to a tumor cell.
  • the polypeptide chain comprises the antigen binding domain ABD3 as disclosed herein and an antigen binding domain that binds to immune cells.
  • the polypeptide chain comprises at least one antigen binding domain selected from ABDI, ABD2 and ABD3 as disclosed herein.
  • the polypeptide chain comprises at least two antigen binding domains selected from ABDI, ABD2 and ABD3 as disclosed herein.
  • the polypeptide chain comprises at least three antigen binding domains selected from ABDI, ABD2 and ABD3 as disclosed herein.
  • the dimerization domain comprises an immunoglobulin dimerization domain.
  • Other dimerization domains known to a person skilled in the art are contemplated herein including leucine zippers, etc.
  • the dimerization domain comprises an IgG, IgM, IgA, IgD or IgE dimerization domain (from human or animal IgGss, IgM, IgAs, IgDs or IgEs).
  • the dimerization domain comprises a CH3 domain of an antibody.
  • the dimerization domain may also comprise a CH2 domain of an antibody.
  • the dimerization domain comprises a natural CH3 domain.
  • the dimerization domain comprises a mutated CH3 domain.
  • the dimerization domain comprises a natural CH2 and a natural CH3 domain.
  • the dimerization domain comprises a natural CH2 and a mutated CH3 domain.
  • the dimerization domain comprises a mutated CH2 and a mutated CH3 domain.
  • the dimerization domain comprises a mutated CH2 and a natural CH3 domain.
  • the dimerization domain does not comprise a CHI domain.
  • the dimerization domain does not comprise a CH4 domain.
  • the dimerization domain comprises a Fc region of an antibody or a portion thereof.
  • the polypeptide chain comprises at least two or at least three antigen binding domains and a dimerization domain that allow assembly of two polypeptide chains to form a multivalent and/or multispecific binding agent.
  • the antigen binding domain comprises or consist of an antigen binding domain of a single domain antibody (sdAb).
  • the antigen binding domain comprises a heavy chain variable region (VH or VHH).
  • the VHH is derived from humans, from a mouse, from a rat etc.
  • the VHH is from a transgenic mouse or rat capable of expressing camelized mouse or rats VHHs, VHHs from other species (e.g., humans etc.) or camelized VHHs from other species (e.g., camelized human VHH etc.).
  • the binding agent does not comprise a light chain variable region (VL or VLL).
  • the binding agent comprises a light chain variable region (VL or VLL).
  • VL light chain variable region
  • the antigen binding domain is a single chain variable fragment (ScFv).
  • the antigen binding domain is from a VNAR fragment.
  • the antigen binding domains of the polypeptide chain comprises a combination of any antigen binding domain of single domain antibodies (sdAbs), heavy chain variable regions (VHs or VHHs), light chain variable regions (VLs or VLLs), single chain variable fragments (ScFvs) and/or VNAR fragments.
  • sdAbs single domain antibodies
  • VHs or VHHs heavy chain variable regions
  • VLs or VLLs light chain variable regions
  • ScFvs single chain variable fragments
  • VNAR fragments single chain variable fragments
  • the sdAb or VHH is from a Camelidae antibody.
  • the Camelidae antibody is from a dromedary, a camel, a llama, an alpaca etc.
  • the sdAb or VHH is from a cartilaginous fish antibody.
  • the cartilaginous fish antibody is a shark antibody.
  • each antigen binding domain specifically binds to a different epitope.
  • each antigen binding domain specifically binds to a different antigen. In yet other embodiments, each antigen binding domain specifically binds to a different protein.
  • the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds to a protein expressed by a tumor. In other embodiments, the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds to a protein expressed by a tumor and that modulates its activity.
  • the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds to an immune checkpoint protein. In other embodiments, the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds to an immune checkpoint protein and that modulates its activity.
  • the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds to an immune cell protein. In other embodiments, the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds to an immune cell protein and that modulates its activity. Yet in other embodiments, the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds to or engages and recruits or redirects immune cells.
  • the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds to peripheral blood mononuclear cells (PBMCs). In other embodiments, the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds to PBMCs and that modulates its activity. Yet in other embodiments, the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds to PBMCs and that recruits or redirects PBMCs.
  • PBMCs peripheral blood mononuclear cells
  • the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds to a T cell protein. In other embodiments, the binding agent may bind to a T cell protein and may modulate its activity. Yet in other embodiments, the binding agent may bind to a T cell protein and may recruit or redirect T cells. In some embodiments the binding agent may bind to activated T cells and/or may modulate the activity of activated T cells. In some embodiments, the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds to a protein expressed by a tumor and at least one antigen binding domain that binds to and recruits or redirects an immune cell.
  • the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds to a protein expressed by a tumor, at least one antigen binding domain that binds to an immune check point protein and at least one antigen binding domain that binds to and recruits or redirects an immune cell.
  • the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that modulates immune checkpoint inhibitors.
  • the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds to a tumor antigen, at least one antigen binding domain that binds to an immune check point protein and at least one antigen binding domain that binds to a T cell.
  • the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds to a tumor antigen, at least one antigen binding domain that binds to an immune check point protein and at least one antigen binding domain that binds to CD47.
  • the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that modulates CD47 function.
  • the binding agent comprises a polypeptide chain comprising at least one antigen binding domain that binds CD47 and enhances macrophage function by blocking SIRPa/CD47 interaction.
  • the binding agent comprises a polypeptide chain comprising an antigen binding domain that specifically binds to a receptor.
  • the binding agent comprises a polypeptide chain comprising an antigen binding domain that specifically binds to a tumor antigen and an antigen binding domain that specifically binds to an immunomodulator.
  • the antigen binding domain that specifically binds to a tumor antigen is N-terminal to the dimerization domain and the antigen binding domain that specifically binds to an immunomodulator is C-terminal to the dimerization domain.
  • the immunomodulator is an immune checkpoint protein, a cytokine, a chemokine or an immune receptor or coreceptor.
  • a given antigen binding domain may bind to an epitope that exists in different proteins.
  • the antigen binding domain, or the binding agent comprising same may bind to more than one protein.
  • the antigen binding domain, or the binding agent may have affinity for more than one protein.
  • the binding agent comprises at least two polypeptide chains which are capable of forming dimers.
  • the two polypeptide chains are the same.
  • the two polypeptide chains are different.
  • the polypeptide chains are the same, and the binding agent is a homodimer.
  • the polypeptide chains are different, and the binding agent is a heterodimer.
  • the binding agent is multispecific.
  • the binding agent is bispecific, trispecific or tetra specific.
  • the binding agent comprises one or more polypeptide chains that are multispecific.
  • the binding agent comprises one or more polypeptide chains that are bispecific, trispecific or tetra specific.
  • the one or more polypeptide chains have the same valency and specificity.
  • the one or more polypeptide chains have different valency and specificity. In some embodiments, the one or more polypeptide chains each is an antibody heavy chain.
  • binding agent of any of the preceding claims, wherein the binding agent is an antibody or an antigen binding fragment thereof.
  • the binding agent is a bispecific antibody.
  • the bispecific antibody further comprises a first antibody light chain and a second antibody light.
  • one or more of the antigen binding domains is humanized.
  • one or more of the antigen binding domains is partially humanized.
  • the antigen binding domains comprise one or more human frameworks.
  • X or Y are independently selected from a linker, a cytokine, a chemokine, a tag, a masking domain, a phage coat protein (pill, pVI, pV, pVII or pIX), an antigen binding domain or combination thereof.
  • the polypeptide chain is conjugated to a therapeutic moiety.
  • the polypeptide chain is conjugated to a detectable moiety.
  • the polypeptide chain is conjugated to a protein allowing an extended half-life.
  • the polypeptide chain is attached to nanoparticles.
  • compositions comprising at least one of the binding agents disclosed herein.
  • the composition comprises monomers, dimers and mixture thereof.
  • greater than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the first and second polypeptide chains exist as homodimers in the composition. In some embodiments, greater than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the first and second polypeptide chains exist as heterodimers in the composition.
  • compositions comprising a binding agent disclosed herein and a pharmaceutically acceptable carrier.
  • nucleic acid or set of nucleic acids encoding the polypeptide chains and/or the binding agent disclosed herein.
  • the nucleic acid may be in the form of DNA segments as disclosed herein.
  • Additional aspects and embodiments of the present disclosure relate to a cell comprising the nucleic acid or the vector disclosed herein.
  • kits comprising the binding agent disclosed herein.
  • kits comprising the nucleic acid disclosed herein.
  • kits comprising the vector disclosed herein.
  • kits comprising the cells disclosed herein.
  • the present disclosure relates to a method of treating a disorder or disease comprising administering the binding agent disclosed herein.
  • the present disclosure relates to a method of treating a disorder or disease comprising administering the composition disclosed herein. In further aspects and embodiments, the present disclosure relates to a method of treating a disorder or disease comprising administering the pharmaceutical composition disclosed herein.
  • the disorder or disease is cancer.
  • the disorder or disease is a solid tumor.
  • the disorder or disease is advanced metastatic solid cancer.
  • the disorder or disease is hematogenous cancer.
  • the disorder or disease is lung cancer.
  • the lung cancer is metastatic.
  • the disorder of disease is small cell lung cancer.
  • the disorder of disease is non small cell lung cancer.
  • the disorder or disease is myeloma.
  • the disorder or disease is prostate cancer.
  • the disorder or disease is breast cancer.
  • the disorder or disease is rectal cancer.
  • the disorder or disease is pancreatic cancer.
  • the disorder or disease is glioblastoma.
  • the disorder or disease is an infection.
  • the disorder or disease is immune dysregulation.
  • the present disclosure relates to a method of making the binding agent disclosed herein, the method comprising transforming cells with one or more vectors comprising the nucleic acid disclosed herein.
  • the method may further comprise isolating and/or purifying the binding agent from impurities.
  • the method may further comprise isolating and/or purifying heterodimers from monomers and/or homodimers. In other embodiments, the method may further comprise isolating and/or purifying homodimers from monomers and/or heterodimers.
  • the method further comprises conjugating the binding agent with a therapeutic moiety, detectable moiety, or a protein allowing an extended half-life or to nanoparticles.
  • Figure 1 graph representing the binding curve of D2-specific binding agent (VHH-hinge- CH2-CH3) on D2 proteoliposomes. Mock proteoliposomes were included as negative control.
  • Figure 2 Table listing the EC50 of D2-specific binding agents (VHH-hinge-CH2-CH3 ) in the GPCR BRET assays transfected with various G protein sensors. Dopamine was used as a positive control to show the GPCR response with G proteins including Gaz, Gai2, GaoA, and Barr2. Negative control is 4HEM-specific binding agent (VHH-hinge-CH2-CH3) comprising the antigen binding domain set forth in SEQ ID NO: 114 (KC018).
  • FIG. 3 Heat map displaying the changes of gene expression in NCI-H69 cells upon treatment with binding agent comprising D2-specific antigen binding domain (VHH-hinge-CH2- CH3) (KC013; SEQ ID NO:73).
  • Negative control is 4HEM-specific binding agent (VHH-hinge- CH2-CH3) comprising the antigen binding domain set forth in SEQ ID NO: 114 (KC018).
  • Figure 4 graph representing the downregulated signaling pathways and protein classes from the PANTHER analysis of the RNAseq result of Figure 3.
  • Figures 5A-5C graph representing the downregulated genes verified by qRT-PCR NCI- H69 ( Figure 5A), NCI-H82 ( Figure 5B), and HEK-D2 (Figure 5C) upon treatment with binding agent comprising D2-specific antigen binding domain (VHH-hinge-CH2-CH3) (KC013; SEQ ID NO:73).
  • Figures 6A-6B graph representing the pharmacokinetics of binding agent comprising D2- specific antigen binding domain (VHH-hinge-CH2-CH3) (KC013; SEQ ID NO:73) and Trastuzumab in SCID mice with single-dose injection (Figure 6A: IV injection) ( Figure 6B: IP injection).
  • Figures 7A-7C graph showing the tumor kinetics and in vivo efficacy of binding agent comprising D2-specific antigen binding domain (VHH-hinge-CH2-CH3, solid line) (KC013; SEQ ID NO:73) in NCG mice with small cell lung cancer (SCLC) xenograft models compared to isotype control (dashed line) in the NCI-H727 tumor prevention model ( Figure 7A), in the NCI- 1169 tumor prevention model ( Figure 7B) or in the NCI-H510A tumor prevention model ( Figure 7C).
  • Negative control is 4HEM-specific binding agent (VHH-hinge-CH2-CH3) comprising the antigen binding domain set forth in SEQ ID NO: 114 (KC018).
  • FIG 8 table listing the percentage of tumor growth inhibition in various tumor prevention SCLC tumor models in SCID mice upon treatment with D2-specific binding agents (VHH-hinge-CH2-CH3) that comprises the amino acid sequence set forth in SEQ ID NO:71 (KC011), SEQ ID NO:72 (KC012), SEQ ID NO:73 (KC013), or SEQ ID NO:74 (KC014).
  • VHH-hinge-CH2-CH3 D2-specific binding agents
  • Figure 9A graph displaying the binding curve of PD- 1 -specific binding agent (KC036; SEQ ID NO: 94) on human, cynomolgus monkey, and rat recombinant PD1 protein or on control protein (BSA). Negative control is a binding agent that comprises HEWL-specific antigen binding domains (KC035: SEQ ID NO:93).
  • Figure 9B graph displaying the binding curve of PD- 1 -specific binding agent (KC036;
  • Negative control is a binding agent that comprises HEWL- specific antigen binding domains (KC035: SEQ ID NO:93).
  • FIG 9C graph displaying the binding curve of CD47-specific binding agent (KC015; SEQ ID NO:75) on human recombinant CD47 protein.
  • Negative control for KC015 is a binding agent that comprises HEWL-specific antigen binding domains (KC016: SEQ ID NO:76).
  • the positive control is monoclonal antibody clone B6H12.
  • the isotype control for clone B6H12 is used as mouse IgG isotype control antibody.
  • Figure 9D graph displaying the binding curve of CD47-specific binding agent KC015 on cynomolgus CD47 protein.
  • Negative control KC016 is a binding agent that comprises HEWL-specific antigen binding domains.
  • the positive control is monoclonal antibody clone B6H12.
  • the isotype control for clone B6H12 is used as mouse IgG isotype control antibody.
  • Figure 9E graph representing the binding curve of CD47-specific binding agent KC015 on various blood cell subtypes including the T cells, monocytes, granulocytes, red blood cells (RBCs), and platelets.
  • Figure 10 graph representing the cell-binding activity of PD-l-specific binding agent (KC036; SEQ ID NO:94) on CHO-PD1 cells ( Figure 10B) and CHO parental cells ( Figure 10A) obtained by flow cytometry.
  • PD-1 antibody A commercially available PD-1 antibody is used as positive control.
  • Negative control is a binding agent that comprises HEWL-specific antigen binding domains (KC035: SEQ ID NO:93).
  • Figure 11 graph representing the cytotoxicity data of PBMC-mediated THP-1 death induced by PD-l-specific binding agent (KC036; SEQ ID NO:94) in the presence CD33 BiTE 48 hours after incubation which was used to activate T cells via CD3 subunits or in the presence of control BiTE.
  • Negative control is a binding agent that comprises HEWL-specific antigen binding domains (KC031 : SEQ ID NO:89).
  • Positive controls include Pembrolizumab and Nivolumab.
  • Figure 12 graph displaying the checkpoint inhibition activity of PD-1 -specific binding agent (KC036; SEQ ID NO:94) using PD-1/PD-L1 blockade bioassay system.
  • This system is an engineered Jurkat cell line expressing luciferase reporter under the NFAT promoter.
  • the negative control is a binding agent that comprises HEWL-specific antigen binding domains (KC035: SEQ ID NO:93).
  • the anti-PD-1 antibody Pembrolizumab is used as a positive control.
  • Figure 13 graph representing the binding data of a trispecific binding agent comprising anti-D2-, anti-PD-1 and anti-CD47 antigen binding domains to HEK293T cells and HEK293T- CD47 KO cells (CD47 knock-out cells) (KC020; SEQ ID NO:77) as well as a monospecific binding agent comprising the same anti-CD47 antigen binding domains (KC015: SEQ ID NO:75 VHH-hinge-CH2-CH3).
  • Negative controls include corresponding formats comprising anti-HEWL antigen binding domains (KC016 (SEQ ID NO:76) and KC039 (SEQ ID NO:97)).
  • a commercially available anti-human CD47 antibody (Clone CC2C6) is used as positive control.
  • Figure 14 graph representing binding of binding agent comprising anti-D2-, and anti- CD47 antigen binding domains on human T cells (KC040: SEQ ID NO:84) compared to control binding agents comprising anti-HEWL antigen binding domains (KC035: SEQ ID NO:93) or anti- CD3 and anti-HEWL antigen binding domains (KC034; SEQ ID NO:92).
  • Figures 15A-15B graph representing the T cell activation ( Figure 15A) and T cell- dependent cytotoxicity ( Figure 15B) at the E to T ratio of 5 : 1 induced by binding agent comprising anti-D2-, and anti-CD47 antigen binding domains on human T cells (KC040: SEQ ID NO: 84).
  • Controls include, medium only (negative control), binding agent comprising anti-HEWL antigen binding domains and the same anti-D2 antigen binding domain (negative control KC032; SEQ ID NO:90) and OKT3 (positive control).
  • Figure 16 graph illustrating T cell activation upon treatment with binding agent comprising D2- and CD47-specific antigen binding domains (KC040: SEQ ID NO:84) in the presence or absence of Concanavalin A.
  • Controls include binding agent comprising HEWL- specific antigen binding domains (KC035: SEQ ID NO:93) or anti-CD3 and anti-HEWL antigen binding domains (positive control KC034; SEQ ID NO:92) or OKT3 (positive control).
  • Figure 17 graph displaying the checkpoint inhibition activity of CD47 specific binding agent (KC015; SEQ ID NO:75) using the Promega CD47/SIRPa blockade bioassay system.
  • This system is an engineered THP-1 cell line expressing luciferase reporter induced by FcyR protein that engages FcyRs.
  • Negative control is a binding agent that comprises HEWL-specific antigen binding domains (KC016: SEQ ID NO:76)
  • the positive control is monoclonal antibody clone B6H12.
  • the isotype control for clone B6H12 is the mouse IgG isotype control antibody.
  • Figure 18 graph representing tumor volume upon treatment with trispecific binding agent comprising anti-D2-, anti-PD-1 and anti-CD47 antigen binding domains (KC021 : SEQ ID NO:78) in established NCI-H82 xenograft model in NCG mice. Negative control includes binding agent comprising HEWL-specific antigen binding domains (KC031 : SEQ ID NO:89).
  • FIGS 19A-19B Plots representing T cell infiltration into NCI-H69 cell clusters upon treatment with binding agent comprising anti-D2 and anti-PD-1 antigen binding domains (KC037;
  • Controls include binding agent comprising HEWL-specific antigen binding domains (KC035: SEQ ID NO:93).
  • Figures 20A-20B graph representing tumor volume ( Figure 20A) and table representing tumor growth inhibition ( Figure 20B) upon treatment with trispecific binding agent comprising varying anti-D2, and same anti -PD- 1 and anti-CD47 antigen binding domains (KC020; SEQ ID NO:77, KC022; SEQ ID NO:79, KC023; SEQ ID NO:80, KC024; SEQ ID NO:81, KC025; SEQ ID NO:82, KC026; SEQ ID NO:83).
  • trispecific binding agent comprising varying anti-D2, and same anti -PD- 1 and anti-CD47 antigen binding domains
  • Figure 21A graph representing tumor volume upon treatment with CD47 specific binding agent (KC015; SEQ ID NO:75) in PBMC pre-engrafted NCI-H82 xenograft model in NCG mice. 10 million PBMC were engrafted into NCG mice 3 days before tumor cell implantation. Treatment started 10 days after PBMC engraftment, twice per week for a total of 8 doses. Negative control used in the study was PBS.
  • CD47 specific binding agent KC015; SEQ ID NO:75
  • Figure 21B Table showing the in vivo efficacy of KC020 (SEQ ID NO:77) using various tumor cells including NCI-H69, NCI-H82, SCLC-21H and RKO in different models.
  • Figure 21C graph representing tumor volume upon treatment with anti-CD47 specific binding agent KC015 in the established MDA-MB-231 xenograft model in SCID mice.
  • the negative control used in the study was PBS.
  • 5 million MDA-MB-231 cells were subcutaneously (s.c.) into the right flank of mice injected into SCID.
  • Mice received the binding agents (8 mg/kg) treatment by intraperitoneal (i.p.), once a week, for a total of eight doses.
  • Figure 22 graph representing tumor volume upon treatment with IgGl or IgG4 isoforms of binding agent comprising anti-D2-, anti-PD-l-and anti-CD47 antigen binding domains (KC028; SEQ ID NO:86; KC029; SEQ ID NO:87, KC027: SEQ ID NO:85).
  • Control includes binding agent comprising anti-HEWL antigen binding domains (KC031: SEQ ID NO:89).
  • Figures 23A-23B illustration of the biodistribution experiment ( Figure 23A) and pictures ( Figure 23B) displaying the accumulation of trispecific binding agent comprising anti-D2, anti- PD-1 and anti-CD47 antigen binding domains (KC021; SEQ ID NO:78) in the NCI-H82 (top panel) and NCI-H69 (bottom panel) xenograft models in NCG mice.
  • Figures 24A-24B graph representing the metastasis of livers from hCD34+ humanized NCG mice bearing established NCI-H69 tumors treated with either PBS or KC020 (SEQ ID NO:77) ( Figure 24A) and H&E staining pictures of tumors indicating the disseminated tumor cells from PBS group but not KC020 (SEQ ID NO:77) group as shown in the black box ( Figure 24B).
  • Figure 24C graph representing tumor kinetics and in vivo efficacy of KC020 in the NCI- H82/PBMC co-engraftment models at an E:T ratio of 1 :5 in NCG mice.
  • Figures 25A-25C graph representing binding of KC020 (SEQ ID NO:77) submitted to stress conditions on D2 proteoliposome (Figure 25A), human recombinant PD- 1 protein ( Figure 25B), and human recombinant CD47 protein ( Figure 25C) as measured by ELISA assay.
  • the stressed conditions include agitation for 3 days, freeze and thaw for five times, and storage at 40 °C for two weeks.
  • Figures 26A-26C graph representing binding of KC020 (SEQ ID NO:77) submitted to low pH stress on D2 proteoliposome (Figure 26A), human recombinant PD-1 protein ( Figure 26B), and human recombinant CD47 protein ( Figure 26C) as measured by ELISA assay.
  • the stressed conditions include treatment at pH 3.5 for 4 hours and 48 hours.
  • Figure 27 graph representing the survival curves of KC020 treated animals implanted with the NCI-H82 SCLC tail vein metastatic model. NCG mice were inoculated with 50,000 NCI-H82 cells, followed by KC020 treatment the next day. KC020 was treated biweekly. Negative control used in the study was PBS.
  • amino acid numbering indicated for the dimerization domain are in accordance with the EU numbering system.
  • treatment refers to both therapeutic treatment and prophylactic or tumor prevention measures. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.
  • the term “about” or “approximately” with respect to a given value means that variation in the value is contemplated. In some embodiments, the term “about” or “approximately” shall generally mean a range within +/- 10 percent, within +/- 5 percent, within +/- 4 percent, within +/- 3 percent, within +/- 2 percent or within +/- 1 percent of a given value or range.
  • the term “functionally active” with reference to an antigen binding domain means that the antigen binding domain is capable of binding to its target and optionally that the antigen binding domain possesses one or more biological activities.
  • the term “flexible linker” refers to peptide comprising at least a portion composed of flexible amino acid residues that allow adjacent modules to move relative to one another.
  • rigid linker refers to peptide comprising at least a portion composed of amino acids that exhibit a rigid structure and that keeps a distance between two modules.
  • helical linker means a linker that is composed of amino acid residues that adopt a a-helical conformation.
  • cleavable linker refers to peptides that comprise an enzymatic cleavage site that is sensitive to proteases selected from ADAMS, AD AMTS, aspartate proteases, caspases, cysteine cathepsins, cysteine proteinases, metalloproteinases, serine proteases, coagulation factor proteases, Type II Transmembrane Serine Proteases (TTSPs) and combination thereof.
  • proteases selected from ADAMS, AD AMTS, aspartate proteases, caspases, cysteine cathepsins, cysteine proteinases, metalloproteinases, serine proteases, coagulation factor proteases, Type II Transmembrane Serine Proteases (TTSPs) and combination thereof.
  • polypeptide chains or binding agents refers to polypeptide chains or binding agents that bind to a single antigen or epitope.
  • a monospecific polypeptide chains or binding agents may thus have one antigen binding domain or more than one binding domains (which are the same or different) having the same specificity towards a given antigen or epitope.
  • multispecific with respect to polypeptide chains or binding agents refers to polypeptide chains or binding agents that bind to more than one antigen or epitope.
  • multispecific encompasses “bispecific”, “trispecific”, “tetraspecific”, “pentaspecific”, “hexaspecific” and the like.
  • binding agent designates a binding agent that binds to two different antigens or proteins or to two epitopes of the same antigen or protein.
  • the expression “at least two polypeptide chains” and the like such as in the expression “binding agent comprises at least two polypeptide chains” and the like refers to a number of polypeptide chain species and not to an absolute numerical value.
  • the term “at least” with respect to a given value intends to include the value and superior values.
  • the term “at least 80%” include “at least 81%”, “at least 82%”, “at least 83%”, “at least 84%”, “at least 85%”, “at least 86%”, “at least 87%”, “at least 88%”,“at least 89%”, “at least 90%”, “at least 91%”, “at least 92%”, “at least 93%”, “at least 94%”, “at least 95%”, “at least 96%”, “at least 97%”, “at least 98%”, “at least 99%” , “at least 99.1%”, “at least 99.2%”, at least 99.3%”, at least 99.4%”, at least 99.5%”, at least 99.6%”, at least 99.7%”, at least 99.8%”, at least 99.9%”, and 100%.
  • the binding agent may comprise one or more antigen binding domains.
  • the antigen binding domains of the present disclosure may be selected for their ability to bind specific targets.
  • the antigen binding domains may also be selected for their in vivo and/or in vitro functional properties or biological effects including, for example, their ability to modulate cellular processes such as gene expression, signal transduction, cell growth, cell viability and the like.
  • the binding agents of the present disclosure comprise one or more antigen binding domains each independently comprising one or more complementarity determining region(s) (CDRs) of an antibody.
  • CDRs complementarity determining region
  • binding agents of the present disclosure may thus be conferred by their antigen binding domains.
  • the binding agent of the present disclosure may comprise an antigen binding domain capable of binding to DR2 or to cells expressing DR2, an antigen binding domain capable of binding to PD-1 or to cells expressing PD-1 and/or an antigen binding domain capable of binding to CD47 or to cells expressing CD47.
  • the antigen binding domain is an antigen binding domain capable of binding to DR2 or to cells expressing DR2 and includes for example, antigen binding domain 1 (ABD1).
  • ABS1 antigen binding domain 1
  • the antigen binding domain is an antigen binding domain capable of binding to PD-1 or to cells expressing PD-1 and includes for example, antigen binding domain
  • the antigen binding domain is an antigen binding domain capable of binding to CD47 or to cells expressing CD47 and includes for example, antigen binding domain
  • the antigen binding domain targets the same epitope or antigen as ABD1, ABD2 and/or ABD3. In some embodiments, the antigen binding domain competes with ABD1, ABD2 and/or ABD3 for binding to their respective epitope or antigen.
  • the antigen binding domain binds to at least one antigen that is not selected amongst DR2, PD-1 or CD47.
  • the binding agent may comprise more than one antigen binding domains.
  • the binding agent may comprise comprises two antigen binding domains or more.
  • the binding agent may comprise three antigen binding domains or more.
  • the binding agent may comprise four antigen binding domains or more.
  • the binding agent may comprise five antigen binding domains or more.
  • the binding agent may comprise six antigen binding domains or more.
  • the binding agent may comprise between one and twelve antigen binding domains, such as between one and two, between one and three, between one and four, between one and five, between one and six, between one and seven, between one and eight, between one and nine, between one and ten, between one and eleven, between one and twelve, between two and three, between two and four, between two and five, between two and six, between two and seven, between two and eight, between two and nine, between two and ten, between two and eleven, between two and twelve, between three and four, between three and five, between three and six, between three and seven, between three and eight, between three and nine, between three and ten, between three and eleven, between three and twelve, between four and five, between four and six, between four and seven, between four and eight, between four and nine, between four and ten, between four and eleven, between four and twelve, between five and six, between five and seven, between five and eight, between five and nine, between five and ten, between five and eleven, between five and twelve, between six and
  • the binding agents of the present disclosure may comprise one or more antigen binding domains and at least one of the antigen binding domains is capable of binding to tumor cells.
  • the binding agents of the present disclosure may comprise one or more antigen binding domains and at least one of the antigen binding domains is capable of binding to an immunomodulator. In some embodiments, at least one of the antigen binding domains is capable of binding to an immune checkpoint protein. In some embodiments, the immune checkpoint protein is PD-1.
  • the binding agents of the present disclosure may comprise one or more antigen binding domains and at least one of the antigen binding domains is capable of binding to immune cells. In some embodiments, at least one of the antigen binding domains is capable of binding to a protein expressed at the surface of immune cells (e.g., T cells, NK-cells, monocytes, macrophages etc.).
  • a protein expressed at the surface of immune cells e.g., T cells, NK-cells, monocytes, macrophages etc.
  • the binding agents of the present disclosure may be multivalent and may comprise at least one antigen binding domain that binds tumor cells and at least one antigen binding domain that binds immune cells.
  • the protein expressed at the surface of immune cells is selected from CD47 or CD3.
  • the protein expressed at the surface of immune cells is CD47.
  • the protein expressed at the surface of immune cells is CD3.
  • the antigen binding domains may be derived from a natural antibody (of human or animal origin) or from a synthetic antibody.
  • antigen binding domains of a natural antibody are engineered so as to form a single chain.
  • antigen binding domains may be obtained from IgGs such as IgGl, IgG2, IgG3 or IgG4.
  • antigen binding domains are derived from a human IgG heavy chain.
  • the antigen binding domains may be obtained from heavy chain only antibodies (HCAbs).
  • HCAbs heavy chain only antibodies
  • antigen binding domains include for example and without limitation a single domain antibody (sdAb), a heavy chain variable region (VH or VHH), a light chain variable region (VL or VLL), a single chain variable fragment (scFv), a V NAR fragment, and combinations thereof.
  • sdAb single domain antibody
  • VH or VHH heavy chain variable region
  • VL or VLL light chain variable region
  • scFv single chain variable fragment
  • V NAR fragment a single chain variable fragment
  • the antigen binding domain of the binding agents disclosed herein is a VHH.
  • the antigen binding domain of the binding agents disclosed herein is a VHH that comprises the complementarity determining regions of the VHH disclosed herein.
  • complementarity determining regions (CDRs) of the VHH disclosed herein correspond to Rabat CDRs.
  • complementarity determining regions (CDRs) of the VHH disclosed herein correspond to IMGT CDRs.
  • the binding agents of the present disclosure may comprise an antigen binding domain VHH derived from humans or a mouse or rat or from a transgenic mouse or rat wherein a mouse or rat VHH has been camelized, a human VHH, a human VHH which has been camelized, of an IgGl, IgG2a, IgG2b, IgG2c or IgG3 or combination thereof.
  • the antibodies may be obtained by immunizing a mouse or a rat or a transgenic mouse or rat which is lacking a functional CHI domain in any of its heavy chains, IgGl, IgG2a, IgG2b, IgG2c or IgG3 or combination thereof, or a combination of the VHH described above, with an antigen of interest.
  • the polypeptide chains of the present disclosure may comprise an antigen binding domain of a camelid antibody such as VHH of an IgG2 or IgG3.
  • the camelid antibodies may be obtained by immunizing a dromedary, a camel, a llama or an alpaca with an antigen of interest.
  • the camelid antibodies may originate from the so-called old-world camelids such as Camelus bactrianus , Camelus dromaderus or from new-world camelids such as Lama pacos, Lama glama and Lama vicugna.
  • the polypeptide chains of the present disclosure may comprise an antigen binding domain of a cartilaginous fish such as a VNAR fragment of IgNAR.
  • the VNAR fragment may originate from shark antibodies.
  • the antigen binding domain of a non-human antibody may be humanized.
  • the framework region of non-human VH, VHH or HCAbs may be modified so as to render them more human-like.
  • Humanization of camelid antibodies is discussed for example in Vincke C. et al. (J.Biol Chem. 2009, 284(5):3273-3284), the entire content of which is incorporated herein by reference.
  • Humanized camelid antibodies may be obtained, for example, by CDR grating onto a universal humanized nanobody scaffold (e.g., h-NbBcII l O R disclosed in Vincke C. et al).
  • VNAR antibodies can be humanized by converting non-CDR residues to those of human germline VKI sequence DPK9 as discussed in Kovalenko OV et al. (J Biol Chem. 2013, 288: 17408-17419) the entire content of which is incorporated herein by reference.
  • the polypeptide chains of the present disclosure therefore encompass humanized antigen binding domains.
  • the antigen binding domain may comprise a human VH (modified or not).
  • Human VH may be obtained for example, from synthetic human VH libraries.
  • Modified human VH include those in which some amino acid residues have been modified to render them more camel-like (i.e., by camelization).
  • antigen binding domains may be incorporated into an antibody, antigen binding fragment or an antibody-like molecule including without limitations, single domain antibodies (sdAb), VHH, conventional antibodies or antigen binding fragments thereof, bispecific antibodies, single chain Fv-CH3 (scFv-CH3) fusion, tandem- scFv-CH3 (TaFv-CH3) fusion, diabody-CH3 (Db-CH3) fusion, tandem Db-CH3 (TaDb-CH3) fusion, single chain Db-CH3 fusion (scDb-CH3), Fab-CH3 fusion, single chain Fab-CH3 fusion, Fab-scFv-CH3 fusion, dual affinity retargeting (DART)-CH3 fusion, Fab-DART-CH3 fusion, single chain Fv- Fc (scFv-Fc) fusion, tandem-scFv-Fc (TaFv-Fc) fusion, diabody-F
  • Antigen binding domain 1 may be selected, for example, from antigen binding domains that bind DR2, some non-limiting exemplary embodiments of which is provided herein.
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABDl) and comprises a heavy chain complementarity determining region 1 (CRDH1) having the amino acid sequence set forth in SEQ ID NO:l, a heavy chain complementarity determining region 2 (CDRH2) having the amino acid sequence set forth in SEQ ID NO:2 and a heavy chain complementarity determining region 3 (CDRH3) having the amino acid sequence set forth in SEQ ID NO:3.
  • ABSl antigen binding domain 1
  • CDRH2 heavy chain complementarity determining region 2
  • CDRH3 heavy chain complementarity determining region 3
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABDl) and comprises a CRDH1 having the amino acid sequence set forth in SEQ ID NO:4, a CDRH2 having the amino acid sequence set forth in SEQ ID NO:5 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO:6.
  • ABSl antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABDl) and comprises a CRDH1 having the amino acid sequence set forth in SEQ ID NO: 8, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 9 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 10.
  • ABSl antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABDl) and comprises a CRDH1 having the amino acid sequence set forth in SEQ ID NO: 11, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 12 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 13.
  • ABS antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a CRDH1 having the amino acid sequence set forth in SEQ ID NO: 15, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 16 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 17.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a CRDH1 having the amino acid sequence set forth in SEQ ID NO: 18, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 19 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO:20.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a CRDH1 having the amino acid sequence set forth in SEQ ID NO:22, a CDRH2 having the amino acid sequence set forth in SEQ ID NO:23 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO:24.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a CRDH1 having the amino acid sequence set forth in SEQ ID NO:25, a CDRH2 having the amino acid sequence set forth in SEQ ID NO:26 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO:27.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a CRDH1 having the amino acid sequence set forth in SEQ ID NO:29, a CDRH2 having the amino acid sequence set forth in SEQ ID NO:30 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 31.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a CRDH1 having the amino acid sequence set forth in SEQ ID NO:32, a CDRH2 having the amino acid sequence set forth in SEQ ID NO:33 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO:34.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a CRDH1 having the amino acid sequence set forth in SEQ ID NO: 36, a CDRH2 having the amino acid sequence set forth in SEQ ID NO:37 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO:38.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a CRDH1 having the amino acid sequence set forth in SEQ ID NO:39, a CDRH2 having the amino acid sequence set forth in SEQ ID NO:40 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO:41.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a CRDH1 having the amino acid sequence set forth in SEQ ID NO:43, a CDRH2 having the amino acid sequence set forth in SEQ ID NO:44 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO:45.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a CRDH1 having the amino acid sequence set forth in SEQ ID NO:46, a CDRH2 having the amino acid sequence set forth in SEQ ID NO:47 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO:48.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a CRDH1 having the amino acid sequence set forth in SEQ ID NO:50, a CDRH2 having the amino acid sequence set forth in SEQ ID NO:51 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO:52.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a CRDH1 having the amino acid sequence set forth in SEQ ID NO:53, a CDRH2 having the amino acid sequence set forth in SEQ ID NO:54 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 55.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:7.
  • the amino acid variation may be located in one or more framework regions of SEQ ID NO :7.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:7 and CDRs identical to the Rabat CDRs of SEQ ID NO: 7.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:7 and CDRs identical to the IMGT CDRs of SEQ ID NO:7.
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:7.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO: 14.
  • the amino acid variation may be located in one or more framework regions of SEQ ID NO: 14.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO: 14 and CDRs identical to the Rabat CDRs of SEQ ID NO: 14.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO: 14 and CDRs identical to the IMGT CDRs of SEQ ID NO: 14.
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:14.
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:21.
  • the amino acid variation may be located in one or more framework regions of SEQ ID NO:21.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:21 and CDRs identical to the Rabat CDRs of SEQ ID NO:21.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:21 and CDRs identical to the IMGT CDRs of SEQ ID NO:21.
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:21.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:28.
  • the amino acid variation may be located in one or more framework regions of SEQ ID NO:28.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:28 and CDRs identical to the Rabat CDRs of SEQ ID NO: 28. In some embodiment, the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:28 and CDRs identical to the IMGT CDRs of SEQ ID NO:28.
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:28.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:35.
  • the amino acid variation may be located in one or more framework regions of SEQ ID NO :35.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:35 and CDRs identical to the Rabat CDRs of SEQ ID NO:35.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:35 and CDRs identical to the IMGT CDRs of SEQ ID NO:35.
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO :35.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:42.
  • the amino acid variation may be located in one or more framework regions of SEQ ID NO:42.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:42 and CDRs identical to the Rabat CDRs of SEQ ID NO: 42.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:42 and CDRs identical to the IMGT CDRs of SEQ ID NO:42.
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:42.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:49.
  • the amino acid variation may be located in one or more framework regions of SEQ ID NO:49.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:49 and CDRs identical to the Rabat CDRs of SEQ ID NO:49.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:49 and CDRs identical to the IMGT CDRs of SEQ ID NO:49.
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:49.
  • ABS1 antigen binding domain 1
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:56.
  • the amino acid variation may be located in one or more framework regions of SEQ ID NO:56.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:56 and CDRs identical to the Rabat CDRs of SEQ ID NO: 56.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:56 and CDRs identical to the IMGT CDRs of SEQ ID NO:56.
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:56.
  • ABS1 antigen binding domain 1
  • Antigen binding domain 2 may be selected, for example, from antigen binding domains that bind PD-1, some non-limiting exemplary embodiments of which is provided herein.
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 2 (ABD2) and comprises a heavy chain complementarity determining region 1 (CRDHl) having the amino acid sequence set forth in SEQ ID NO:57, a heavy chain complementarity determining region 2 (CDRH2) having the amino acid sequence set forth in SEQ ID NO:58 and a heavy chain complementarity determining region 3 (CDRH3) having the amino acid sequence set forth in SEQ ID NO:59.
  • ABS2 antigen binding domain 2
  • CRDHl heavy chain complementarity determining region 1
  • CDRH2 heavy chain complementarity determining region 2
  • CDRH3 heavy chain complementarity determining region 3
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 2 (ABD2) and comprises a CRDHl having the amino acid sequence set forth in SEQ ID NO: 60, a CDRH2 having the amino acid sequence set forth in SEQ ID NO:61 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO:62.
  • ABS2 antigen binding domain 2
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 2 (ABD2) and comprises a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:63.
  • the amino acid variation may be located in one or more framework regions of SEQ ID NO:63.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:63 and CDRs identical to the Rabat CDRs of SEQ ID NO:63.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:63 and CDRs identical to the IMGT CDRs of SEQ ID NO:63.
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 2 (ABD2) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:63.
  • ABS2 antigen binding domain 2
  • Antigen binding domain 3 may be selected, for example, from antigen binding domains that bind CD47, some non-limiting exemplary embodiments of which is provided herein.
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 3 (ABD3) and comprises a heavy chain complementarity determining region 1 (CRDHl) having the amino acid sequence set forth in SEQ ID NO: 64, a heavy chain complementarity determining region 2 (CDRH2) having the amino acid sequence set forth in SEQ ID NO:65 and a heavy chain complementarity determining region 3 (CDRH3) having the amino acid sequence set forth in SEQ ID NO:66.
  • ABS3 antigen binding domain 3
  • CRDHl heavy chain complementarity determining region 1
  • CDRH2 heavy chain complementarity determining region 2
  • CDRH3 heavy chain complementarity determining region 3
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 3 (ABD3) and comprises a CRDHl having the amino acid sequence set forth in SEQ ID NO: 67, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 68 and a CDRH3 having the amino acid sequence set forth in SEQ ID NO:69.
  • ABS3 antigen binding domain 3
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 3 (ABD3) and comprises a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:70.
  • the amino acid variation may be located in one or more framework regions of SEQ ID NO:70.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:70 and CDRs identical to the Rabat CDRs of SEQ ID NO: 70.
  • the heavy chain comprises an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:70 and CDRs identical to the IMGT CDRs of SEQ ID NO:70.
  • the binding agent of the present disclosure may comprise one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 3 (ABD3) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:70.
  • ABS3 antigen binding domain 3
  • the binding agent comprises one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1), an antigen binding domain 2 (ABD2) or an antigen binding domain 3 (ABD3) and wherein at least one antigen binding domains binds to a different antigen.
  • ABS1 antigen binding domain 1
  • ABS2 antigen binding domain 2
  • ABS3 antigen binding domain 3
  • the binding agents may thus comprise an antigen binding domain that binds to CD3.
  • antigen binding domains include those known to a person skilled in the art.
  • An exemplary embodiment of an antigen binding domain that binds to CD3 is provided in SEQ ID NO: 115.
  • the binding agents may comprise an antigen binding domain that binds to DR2, PD-1 and/or CD3. In other embodiments, the binding agents may comprise an antigen binding domain that binds to DR2 and/or CD3. In yet other embodiments, the binding agents may comprise an antigen binding domain that binds to PD-1 and/or CD3.
  • the binding agent comprises one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1), an antigen binding domain 2 (ABD2) or an antigen binding domain 3 (ABD3) and wherein at least one of the antigen binding domains is selected, for example and without limitations, from antigen binding domains that specifically bind to CD3, CD36, DRD1, DRD2, DRD3, DRD4, DRD5, PD- Ll, TROP2, CD 147, MCT1, IL1RAP, AMIG02, PTK7, MCT2, MCT4, NHE1, H+/K+-ATPase, LAP, HLA-I A2, CD73, CD98, CEACAM5/6, ICAM-1, MCSP, fibronectin, Beta 1 Integrin, Tetraspanin 8, CD164, CD59, CD63, CD44, CD166, cWF, TNF, IL-17A, IL17-F, IL-6R, BCMA, TNF
  • binding agents of the present disclosures comprise one or more polypeptide chains.
  • Segments of DNA encoding desired polypeptide chain sequences may be synthesized in vitro.
  • the different DNA modules are assembled into a single piece in an organized and directional manner which is then cloned into an expression vector.
  • the resulting polypeptide chains are therefore composed of different modules forming a single chain.
  • polypeptide chains of the present disclosure include, for example and without limitation, antigen binding domains, linkers and a dimerization domain that promote assembly of at least two polypeptide chains.
  • polypeptide chain of the present disclosure may be monospecific. In some embodiments, the polypeptide chain of the present disclosure may be multispecific.
  • polypeptide chain of the present disclosure may be monovalent.
  • polypeptide chain of the present disclosure may be multivalent.
  • the polypeptide chain does not comprise a dimerization domain.
  • the polypeptide chain comprises a dimerization domain.
  • polypeptide chains may be monospecific.
  • An exemplary embodiment of a monospecific polypeptide chain includes a polypeptide chain that comprise one antigen binding domain.
  • Another exemplary embodiment of a monospecific polypeptide chain includes a polypeptide chain that comprise more than one antigen binding domains, but the antigen binding domains have identical CDRs and framework regions.
  • Yet another exemplary embodiment of a monospecific polypeptide chain includes a polypeptide chain that comprise more than one antigen binding domains, but the antigen binding domains have identical CDRs and different framework regions.
  • a further exemplary embodiment of a monospecific polypeptide chain includes a polypeptide chain that comprise antigen binding domains that differ in the amino acid sequence of one or more of their CDRs (e.g., conservative substitution in one or more CDRs) without affecting their ability to bind to the same antigen or epitope.
  • the polypeptide chains may be multispecific.
  • the polypeptide chains may encompass for example, bispecific polypeptide chains, trispecific polypeptide chains, tetraspecific polypeptide chains, pentaspecific polypeptide chains, hexaspecific polypeptide chains, biparatopic polypeptide chains, multiparatopic polypeptide chains and the like.
  • one or more antigen binding domains may be located at the N-terminus, at the C-terminus or on each side of the dimerization domain.
  • the polypeptide chains may comprise at least one antigen binding domain at the N-terminus of the dimerization domain and at least one antigen binding domain at the C-terminus of the dimerization domain. In a further exemplary configuration, the polypeptide chains may comprise one antigen binding domain at the N-terminus of the dimerization domain and at least two antigen binding domains at the C-terminus of the dimerization domain.
  • the polypeptide chains may comprise two antigen binding domains at the N-terminus of the dimerization domain and two antigen binding domains at the C-terminus of the dimerization domain.
  • polypeptide chains may comprise in aN- to C-terminal fashion an amino acid sequence of formula I:
  • n 0, 1, 2 or an integer greater than 2;
  • n 0, 1, 2 or an integer greater than 2;
  • Ab a , Ab d each represents an antigen binding domain wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1), an antigen binding domain 2 (ABD2) or an antigen binding domain 3 (ABD3);
  • X or Y are independently present or absent and comprises an amino acid sequence
  • L b , L c each independently comprises one or more linkers; and wherein DD represents a dimerization domain.
  • L b may be absent.
  • L c may be absent.
  • both L b and L c may be absent.
  • polypeptide chain comprises more than one antigen binding domains.
  • the [(Ab a )-(L b )] units is the same. In other embodiments where m is 2 or an integer greater than 2, the [(Ab a )-(L b )] units of the polypeptide chain or binding agent is different.
  • the [(Ab a )-(L b )] units of the polypeptide chain or binding agent may comprise the same and different units.
  • n 2 or an integer greater than 2
  • the [(L c )-(Ab d )] units are the same.
  • n 2 or an integer greater than 2
  • the [(L c )-(Ab d )] units are different.
  • the [(L c )-(Ab d )] units comprise the same and different units.
  • each Ab a is the same or different.
  • each Ab d is the same or different.
  • Ab a represents ABD1.
  • Ab d represents ABD2.
  • Ab d represents ABD3.
  • m is 1 and Ab a represents ABD1.
  • n is 2 and one of Ab d represents ABD2.
  • n is 2 and one of Ab d represents ABD3.
  • n is 2 and one of Ab d represents ABD2 and the other Ab d represents
  • m is 2, 3, 4, 5 or an integer greater than 5.
  • n 2 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 + (0.05 * (1 +
  • m is 3.
  • n is 4. In further embodiments m is 5
  • n is an integer greater than 5.
  • n is 2, 3, 4, 5 or an integer greater than 5.
  • n is 2.
  • n 3.
  • n 4.
  • n is 5.
  • n is an integer greater than 5.
  • the one or more polypeptide chain further comprises a hinge region of an antibody or antigen binding fragment thereof.
  • the hinge region is at the N-terminus of the dimerization domain.
  • L b is a hinge region of an antibody or antigen binding fragment thereof.
  • the hinge region is a natural human IgGl hinge region . In other embodiments the hinge region is a mutated human IgGl hinge region.
  • the hinge region is a natural human IgG2 hinge region. In other embodiments, the hinge region is a mutated human IgG2 hinge region.
  • the hinge region is a natural human IgG3 hinge region. In other embodiments, the hinge region is a mutated human IgG3 hinge region.
  • the hinge region is a natural human IgG4 hinge region. In other embodiments, the hinge region is a mutated human IgG4 hinge region.
  • each of the one or more linkers independently has at least 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 amino acid residues in length.
  • each of the one or more linkers is independently a flexible linker, a helical linker, or a rigid linker.
  • the linker L c is a rigid linker. In some embodiments, Lc comprises a non-cleavable linker. In other embodiments, Lc consists of a non-cleavable linker.
  • the one or more linkers comprise a flexible linker.
  • the one or more linkers comprise a rigid linker.
  • the flexible linker is a GS linker.
  • the flexible linker comprises one or more units of GGGGS.
  • the flexible linker comprises at least 2, 3, 4, 5, or more units of GGGGS.
  • the rigid linker comprises multiple PA repeats.
  • the rigid linker is selected from PAPAPKA (SEQ ID NO: 105); APAPAPAPAPKA (SEQ ID NO: 106); APAPAPAPAPAPAPAPAPKA (SEQ ID NO: 107); or combinations thereof.
  • the helical linker comprises one or more units of EAAAK.
  • the helical linker is selected from AEAAAKEAAAKA (SEQ ID NO: 109); AEAAAKEAAAKEAAAKA (SEQ ID NO: 110);
  • AEAAAKEAAAKEAAAKEAAAKEAAAKA (SEQ ID NO: 111); or combinations thereof.
  • the dimerization domain comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 116.
  • the dimerization domain further comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 117.
  • polypeptide chain comprises formula II:
  • polypeptide chain comprises formula III:
  • polypeptide chain comprises formula IV:
  • polypeptide chain comprises formula V:
  • polypeptide chain comprises formula VI:
  • the polypeptide chain comprises formula VII: X-(Abai)-(Lb3)-(Aba2)-(Lb2)-(Aba3)-(Lbi)-(DD)-(Lci)-(Abdi)-(L C2 )-(Abd2)-Y (formula
  • polypeptide chain comprises formula VIII:
  • Ab ai, Ab a2 , Ab a3, Abdi, Abd2, Abd 3 each independently comprises an antigen binding domain.
  • Ab ai, Ab a2 , Ab a3, Abdi, Abd2, Abd 3 each independently represents an antigen binding domain.
  • At least one of the antigen binding domains is an antigen binding domain 1 (ABDI), an antigen binding domain 2 (ABD2) or an antigen binding domain 3 (ABD3)
  • L bi comprises a linker or linkers and/or a hinge region of an antibody or antigen binding fragment thereof. In some embodiments, L bi is L b .
  • L b2 , L b3 L c1 , L c2, and L C3 each independently comprise a linker or linkers.
  • L bi , L b 2 and/or L b 3 may be absent.
  • L b2 and/or L b3 may be absent.
  • one or more of L ci , L c2, and/or L C3 may be absent.
  • L c2 and/or L C3 may be absent.
  • L ci is a rigid linker. In some embodiments, L C2 is a rigid linker.
  • L C3 is a rigid linker
  • L ci , and L C2 are rigid linkers.
  • L ci , L C2 and L C3 are rigid linkers.
  • L ci , L C2 and/or L C3 may be absent.
  • L C2 , and/or L C3 may be absent.
  • L ci , and/or L C3 may be absent.
  • L C2 and/or L C3 may be absent.
  • L ci , L C2 , and L C3 may be absent.
  • polypeptide chains of the present disclosure comprise antigen binding domains that are functionally active either as a single chain or when part of the binding agent disclosed herein.
  • the antigen binding domain of the polypeptide chains may bind to its target and may biologically active.
  • the biological activity of an antigen binding domain includes, for example and without limitation, blocking binding of a target to its natural receptor or ligand.
  • the biological activity of an antigen binding domain includes its ability to sequester a target.
  • the biological activity of an antigen binding domain includes its ability to induce signalling.
  • a polypeptide chain that comprises more than one antigen binding domain is characterized as being multivalent.
  • polypeptide chain of the present disclosure may comprise an additional amino acid sequence at its N- or C- terminus or at both ends (defined by X and Y respectively in the formulas disclosed herein).
  • the amino acid sequence at the N-terminus may include a signal peptide, an exemplary embodiment of which is provided in SEQ ID NO: 133.
  • the amino acid sequence at the N-terminus (defined by X) or C- terminus (defined by Y) may independently include a linker, a cytokine, a chemokine, a tag (e.g., His tag (e.g. SEQ ID NO: 134), a masking domain, a phage coat protein, an antigen binding domain or combination thereof.
  • An exemplary embodiment of a multispecific polypeptide chain include a polypeptide chain that comprises at least two antigen binding domains that differ in the amino acid sequence of one or more of their CDRs leading to different binding specificities.
  • a polypeptide chain may more particularly be characterized as being bispecific when it binds to two different epitopes or antigens.
  • a polypeptide chain may be characterized as being trispecific when it binds to three different epitopes or antigens.
  • a polypeptide chain may be characterized as being tetraspecific when it binds to four different epitopes or antigens.
  • a polypeptide chain may be characterized as being pentaspecific when it binds to five different epitopes or antigens.
  • a polypeptide chain may be characterized as being hexaspecific when it binds to six different epitopes or antigens.
  • a polypeptide chain comprising two antigen binding domains that bind to two non overlapping epitopes on the same target is characterized as being biparatopic.
  • a polypeptide chain comprising antigen binding domains that bind to three, four or more epitopes on the same target is characterized as being multiparatopic.
  • the antigen binding domains of a given polypeptide chain will be selected based on the intended use such as detection, diagnostic and/or therapeutic use. Each of the antigen binding domains of a particular polypeptide chain may be selected so as to generate an additive or synergic effect.
  • the antigen binding domain may be selected for its ability to specifically binds a protein involved in a disease or condition.
  • polypeptide chains of the present disclosure may comprise at least one antigen binding domain that specifically binds to an antigen expressed by tumor cells or by the tumor cell environment (i.e., tumor-specific antigen binding domains).
  • the polypeptide chains may comprise at least one antigen binding domain that specifically binds to an immunomodulator.
  • the polypeptide chain may comprise one or more antigen binding domains that bind an immune checkpoint protein, a cytokine, a chemokine or an immune receptor or coreceptor etc. (e.g., immune-specific antigen binding domains).
  • the antigen binding domain may bind to dopamine receptor D2 (DR2).
  • DR2 dopamine receptor D2
  • the antigen binding domain may bind to PD1.
  • the antigen binding domain may bind to CD47.
  • the polypeptide chain of the present disclosure may comprise at least one tumor-specific antigen binding domain and at least one immune-specific antigen binding domain.
  • the tumor-specific antigen binding domain(s) may be located at the N-terminus of the dimerization domain.
  • the tumor-specific antigen binding domain(s) may be located at the C-terminus of the dimerization domain.
  • the tumor-specific antigen binding domains may be located at both the N- and C-terminus of the dimerization domain.
  • the more immune-specific antigen binding domain(s) may be located at the N-terminus of the dimerization domain.
  • the immune-specific antigen binding domain(s) may be located at the C-terminus of the dimerization domain.
  • the immune-specific antigen binding domains may be located at both the N- and C-terminus of the dimerization domain.
  • the polypeptide chain or binding agent may comprise two immune-specific antigen binding domains at the C-terminus of the dimerization domain.
  • the immune-specific antigen binding domain that is immediately adj acent to the C-terminal part of the dimerization domain may be linked via a non-cleavable linker.
  • the polypeptide chains of the present disclosure comprise a dimerization domain.
  • two polypeptide chains may assemble to form a binding agent.
  • binding agent include homodimers and heterodimers.
  • the dimerization domain may comprise, for example and without limitation, constant regions of an immunoglobulin, including for example a Fc, CH2 and/or CH3 domain of a heavy chain immunoglobulin.
  • the dimerization domain may have a sequence identical to that of a natural IgGl, IgG2, IgG3 or IgG4 constant region or with their corresponding CH2 and/or CH3 domains.
  • dimerization domains having a sequence identical to that of a natural human antibody.
  • dimerization domains include for example a CH2-CH3 domain of a natural human heavy chain.
  • the dimerization domain comprises a natural constant region of an antibody, such as for example, a natural human IgGl constant region, a natural human IgG2 constant region, a natural human IgG3 constant region or a natural human IgG4 constant region.
  • the dimerization domain comprises a natural CH3 domain.
  • the dimerization domain comprises a natural human CH3 domain.
  • the dimerization domain comprises a natural CH2 domain and a natural CH3 domain.
  • the natural CH3 domain is a natural IgGl CH3 domain. In some embodiments, the natural CH3 domain is a natural human IgGl CH3 (e.g., SEQ ID NO: 116).
  • the natural CH3 domain is a natural IgG2 CH3 domain. In other embodiments, the natural CH3 domain is a natural human IgG2 CH3 domain.
  • the natural CH3 domain is a natural IgG3 CH3 domain. In other embodiments, the natural CH3 domain is a natural human IgG3 CH3 domain. In some embodiments, the natural CH3 domain is a natural IgG4 CH3 domain. In some embodiments, the natural CH3 domain is a natural human IgG4 CH3 domain.
  • the binding agent When the two polypeptide chains of the binding agent are composed of the same amino acid sequence, the binding agent will form a homodimer. However, co-expression of polypeptide chains having a CH2-CH3 domain of a natural antibody, but different amino acid sequence may result in a mixture of homodimers and heterodimers.
  • the different binding agents present in a mixture may be separated by methods known in the art and including for example, size-exclusion chromatography.
  • Exemplary heterodimers of the present disclosure therefore include those having a CH3 domain or a CH2-CH3 domain of a natural antibody and that are formed by two polypeptide chains having different sequences or configurations.
  • the polypeptide chains may have a mutated dimerization domain that comprises, for example, from 1 to 30, from 1 to 20, from 1 to 15, from 1 to 10, from 1 to 9, from 1 to 8, from 1 to 7, from 1 to 6, from 1 to 5, from 1 to 4, from 1 to 3 amino acid substitutions in comparison with a natural or wild type sequence.
  • mutated dimerization domains may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions.
  • Amino acid substitutions may be conservatives or nonconservatives as outlined in Table 2.
  • the polypeptide chains may have a mutated dimerization domain having a sequence which is from 80% to 99% identical with that of a natural IgGl, IgG2, IgG3 or IgG4 constant region or with a CH2 and/or CH3 domain.
  • Polypeptide chains encompassed by the present disclosure include those comprising a mutated dimerization domain that is from 85% to 99% identical, from 90% to 99% identical, from 95% to 99% identical with that of a natural IgGl, IgG2, IgG3 or IgG4 constant region or with a CH2 and/or CH3 domain.
  • the polypeptide chains of the present disclosure may comprise a mutated dimerization domain comprising amino acid substitutions that favorize heterodimer formation. Heterodimers of the present disclosure may therefore be formed by polypeptide chains comprising such mutations.
  • the dimerization domain comprises a mutated constant region of an antibody, such as for example, a mutated human IgGl constant region, a mutated human IgG2 constant region, a mutated human IgG3 constant region or a mutated human IgG4 constant region.
  • a mutated constant region may have one or more amino acid substitutions, amino acid insertion or amino acid deletion in comparison with a natural constant region.
  • the dimerization domain comprises a mutated CH3 domain.
  • a mutated CH3 domain may have one or more amino acid substitutions, amino acid insertion or amino acid deletion in comparison with a natural CH3 domain.
  • the dimerization domain comprises a natural CH2 and a mutated CH3 domain.
  • the dimerization domain comprises a mutated CH2 and a mutated CH3 domain.
  • a mutated CH2 domain may have one or more amino acid substitutions, amino acid insertion or amino acid deletion in comparison with a natural CH2 domain.
  • the mutated CH3 domain is a mutated IgGl CH3 domain. In other embodiments, the mutated CH3 domain is a mutated human IgGl CH3 domain.
  • the mutated CH3 domain is a mutated IgG2 CH3 domain. In other embodiments, the mutated CH3 domain is a mutated human IgG2 CH3 domain.
  • the mutated CH3 domain is a mutated IgG3 CH3 domain. In other embodiments, the mutated CH3 domain is a mutated human IgG3 CH3 domain.
  • the mutated CH3 domain is a mutated IgG4 CH3 domain. In other embodiments, the mutated CH3 domain is a mutated human IgG4 CH3 domain.
  • the mutated CH2 domain is a mutated IgGl CH2 domain. In other embodiments, the mutated CH2 domain is a mutated human IgGl CH2 domain.
  • the mutated CH2 domain is a mutated IgG2 CH2 domain. In other embodiments, the mutated CH2 domain is a mutated human IgG2 CH2 domain.
  • the mutated CH2 domain is a mutated IgG3 CH2 domain. In other embodiments, the mutated CH2 domain is a mutated human IgG3 CH2 domain. In some embodiments, the mutated CH2 domain is a mutated IgG4 CH2 domain. In other embodiments, the mutated CH2domain is a mutated human IgG4 CH2 domain.
  • the Fc region may be modified so as to prevent glycosylation, to extend its half-life, to modulate receptor binding or effector function.
  • Exemplary mutations are discussed in Saunders K.O. (Front. Immunol. 10:1296, 2019 the entire content of which is incorporated herein by reference) and include for example mutation of asparagine 297 (e.g., N297).
  • the mutated CH3 domain comprises one or more mutations in comparison with a natural CH3 domain.
  • the dimerization domain comprises a mutated CH3 domain comprising one or more mutations in comparison with a natural CH3 domain.
  • the mutated CH3 domain may comprise one or more mutations in comparison with a natural CH3 domain of a human IgGl .
  • the mutated CH3 domain may comprise one or more mutations in comparison with a natural CH3 domain of a human IgG2.
  • the mutated CH3 domain may comprise one or more mutations in comparison with a natural CH3 domain of a human IgG3.
  • the mutated CH3 domain may comprise one or more mutations in comparison with a natural CH3 domain of a human IgG4.
  • the mutated CH3 domain may include amino acid substitutions at position 356, 357, 370, 399 and/or 439 (in accordance with EU numbering system).
  • the dimerization domain comprises a mutated CH3 domain comprising one or more mutations at positions corresponding to D399, D/E356 and/or K370 (in accordance with EU numbering system) in comparison with a natural CH3 domain of a human IgGl or IgG4.
  • the dimerization domain comprises a mutated CH3 domain comprising one or more mutations at positions corresponding to D399, E357 and/or K439 in accordance with EU numbering (in accordance with EU numbering system) in comparison with a natural CH3 domain of a human IgGl or IgG4.
  • the mutated CH3 domain further comprises one or more mutations at positions corresponding to Y349, T350, L351, P352, S354, R/Q355, T394 and/or P395 in accordance with EU numbering (in accordance with EU numbering system) in comparison with a natural CH3 domain of a human IgGl or IgG4.
  • one polypeptide chain of a given binding agent may include a mutated CH3 domain having, for example, amino acid substitutions at positions 357, 399 and 439, whereas the other polypeptide chain of the binding agent may include a mutated CH3 domain having, for example, amino acid substitutions at positions 356, 370 and 399 (in accordance with EU numbering system).
  • one polypeptide chain of a given binding agent may include a mutated CH3 domain having, for example, amino acid substitutions at positions 357, 399 and 439, whereas the other polypeptide chain of the binding agent may include a mutated CH3 domain having, for example, amino acid substitutions at positions 356, 370 and 399 (in accordance with EU numbering system).
  • One or both polypeptide chains of a given binding agent may optionally further comprise mutations at positions selected from 349, 350, 351, 352, 354, 355, 394 and/or 395.
  • One polypeptide chain of a given binding agent may thus comprise a first dimerization domain (DDi) having the amino acid sequence disclosed herein and the other polypeptide chain of a given binding agent may thus comprise a second dimerization domain (DD 2 ) having the amino acid sequence disclosed herein.
  • DDi first dimerization domain
  • DD 2 second dimerization domain
  • the amino acid at position 356 may be replaced by a neutral amino acid.
  • the amino acid at position 370 may be replaced by a positively charged amino acid.
  • the amino acid at position 399 may be replaced by a neutral amino acid.
  • the amino acid at position 357 may be replaced by a neutral amino acid.
  • the amino acid at position 439 may be replaced by a negatively charged amino acid.
  • one of the polypeptide chain may be mutated by replacing a) the aspartic acid (D) or glutamic acid (E) at position 356 for a neutral amino acid, b) the lysine (K) at position 370 for a positively charged amino acid and c) the aspartic acid (D) at position 399 for a neutral amino acid while the other polypeptide chain may be mutated by replacing a) the glutamic acid (E) at position 357 for a neutral amino acid, b) the aspartic acid (D) at position 399 for a neutral amino acid and c) the lysine (K) at position 439 for a negatively charged amino acid.
  • An exemplary embodiment of the polypeptide chains of the present disclosure may comprise a dimerization domain comprising a mutated CH3 domain in which the aspartic acid (D) or glutamic acid (E) at position 356 may be changed for glutamine (Q), the lysine (K) at position 370 may be changed for glutamic acid (E) and the aspartic acid (D) at position 399 may be changed for asparagine (N).
  • polypeptide chains of the present disclosure may comprise a dimerization domain comprising a mutated CH3 domain in which the glutamic acid (E) at position 357 may be changed for glutamine (Q), the aspartic acid (D) at position 399 may be changed for asparagine (N) and the lysine (K) at position 439 may be changed for glutamic acid (E).
  • the dimerization domain comprises a mutated CH3 domain in which the amino acid substitution (in comparison with natural CH3 domain) is selected from: a. an amino acid substitution at position D399; b. an amino acid substitution at position D/E356; c. an amino acid substitution at position E357; d. an amino acid substitution at position K370; e. amino acid substitution at position K439; f. an amino acid substitution at position Y349; g. an amino acid substitution at position T350; h. an amino acid substitution at position L351 ; i. an amino acid substitution at position P352; j. an amino acid substitution at position S354; k. an amino acid substitution at position R355; l.
  • the mutated CH3 domain may comprise amino acid substitutions at positions D399, D/E356, K370 and Y349.
  • the mutated CH3 domain may comprise amino acid substitutions at positions D399, D/E356, K370 and T350.
  • the mutated CH3 domain may comprise amino acid substitutions at positions D399, D/E356, K370 and L351.
  • the mutated CH3 domain may comprise amino acid substitutions at positions D399, D/E356, K370 and P352.
  • the mutated CH3 domain may comprise amino acid substitutions at positions D399, D/E356, K370 and S354.
  • the mutated CH3 domain may comprise amino acid substitutions at positions D399, D/E356, K370 and R355.
  • the mutated CH3 domain may comprise amino acid substitutions at positions D399, D/E356, K370 and Q355.
  • the mutated CH3 domain may comprise amino acid substitutions at positions D399, D/E356, K370 and T394.
  • the mutated CH3 domain may comprise amino acid substitutions at positions D399, D/E356, K370, Y349 and S354.
  • the mutated CH3 domain may comprise amino acid substitutions at positions D399, K439, E357 and Y349.
  • the mutated CH3 domain comprises amino acid substitutions at positions D399, E357, K439 and T350.
  • the mutated CH3 domain comprises amino acid substitutions at positions D399, E357, K439E and L351. In some embodiments, the mutated CH3 domain may comprise amino acid substitutions at positions D399, K439, E357 and P352.
  • the mutated CH3 domain may comprise amino acid substitutions at positions D399, K439, E357 and S354.
  • the mutated CH3 domain may comprise amino acid substitutions at positions D399, K439, E357 and R355.
  • the mutated CH3 domain may comprise mutations at positions D399, K439, E357 and Q355.
  • the mutated CH3 domain may comprise amino acid substitutions at positions D399, K439, E357 and P395.
  • the mutated CH3 domain comprises amino acid substitutions at positions D399, E357, K439, Y349 and S354.
  • the amino acid substitution at position Y349 is selected from Y349K, Y349D or Y349R. More particularly, in some embodiments, the amino acid substitution at position Y349 is Y349K. In other embodiments, the amino acid substitution at position Y349 is Y349D.
  • the amino acid substitution at position S354 is selected from S354K, S354D, S354W or S354M. More particularly, in some embodiments, the amino acid substitution at position S354 is S354K. In other embodiments, the amino acid substitution at position S354 is S354D. In other embodiments, the amino acid substitution at position S354 is S354M.
  • the amino acid substitution at position L351 is L351Y, L351W, L351H, L351R, L351D, L351A, L351T. More particularly, in some embodiments, the amino acid substitution at position L351 is L351Y. In other embodiments, the amino acid substitution at position L351 is L351W. In other embodiments, the amino acid substitution at position L351 is L351R. In some embodiments, the amino acid substitution at position T350 is T350L, T350I or T350V. More particularly, in some embodiments, the amino acid substitution at position T350 is T350I. In other embodiments, the amino acid substitution at position T350 is T350V.
  • the amino acid substitution at position P352 is P352Y, P352V, P352R, P352T, P352L, P352G, P352E, P352C, P352K or P352D. More particularly, in some embodiments, the amino acid substitution at position P352 is P352R. In other embodiments, the amino acid substitution at position P352 is P352E.
  • the amino acid substitution at position T394 is T394N.
  • the amino acid substitution at position P395 is P395I. In other embodiments, the amino acid substitution at position P395 is P395G. In other embodiments, the amino acid substitution at position P395 is P395E.
  • the amino acid substitution at position R355 is R355K. In other embodiments, the amino acid substitution at position R355 is R355W.
  • the amino acid substitution at position Q355 is Q355K. In other embodiments, the amino acid substitution at position Q355 is Q355W.
  • the mutated CH3 domain comprises mutations D399N, D/E356Q and K370E in accordance with EU numbering.
  • the mutated CH3 domain comprises mutations D399Q, D/E356Q and K370E in accordance with EU numbering.
  • the mutated CH3 domain comprises mutations D399N, E357Q and K439E in accordance with EU numbering.
  • the mutated CH3 domain may comprise mutations D399Q, D/E356Q, K370E, Y349K and S354K.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and L351W.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and S354M. In some embodiments, the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and T350I.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and T350V.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and P352R.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and P352E.
  • the mutated CH3 domain may comprise mutations D399Q, D/E356Q and K370E.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and L351 Y.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E, and L351H.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E, and R355K.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E, and Q355K.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and S354K.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and T350L.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and T394N.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and P352Y. In some embodiments, the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and P352V.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and P352T.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and P352L.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and P352G.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and P352C.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and L351T.
  • the mutated CH3 domain may comprise mutations D399N, D/E356Q, K370E and L351 A.
  • the mutated CH3 domain comprises mutations D399Q, E357Q, K439E, Y349D and S354D.
  • the mutated CH3 domain comprises mutations D399N, E357Q, K439E and L351R.
  • the mutated CH3 domain comprises mutations D399N, E357Q, K439E and L351Y.
  • the mutated CH3 domain comprises mutations D399N, E357Q, K439E and T350I.
  • the mutated CH3 domain may comprise mutations D399N, E357Q, K439E and T350V.
  • the mutated CH3 domain may comprise mutations D399Q, K439E,
  • the mutated CH3 domain may comprise mutations D399N, K439E, E357Q, S354K.
  • the mutated CH3 domain may comprise mutations D399N, K439E, E357Q, S354W.
  • the mutated CH3 domain may comprise mutations D399N, K439E, E357Q, Y349R.
  • the mutated CH3 domain may comprise mutations D399N, K439E, E357Q, T350L.
  • the mutated CH3 domain may comprise mutations D399N, K439E, E357Q, R355W.
  • the mutated CH3 domain may comprise mutations D399N, K439E, E357Q, Q355W.
  • the mutated CH3 domain may comprise mutations D399N, K439E, E357Q, P395I.
  • the mutated CH3 domain may comprise mutations D399N, K439E, E357Q, P395G.
  • the mutated CH3 domain may comprise mutations D399N, K439E, E357Q, P395E.
  • the mutated CH3 domain may comprise mutations D399N, K439E, E357Q, P352K.
  • the mutated CH3 domain may comprise mutations D399N, K439E, E357Q, P352D.
  • the mutated CH3 domain may comprise mutations D399N, K439E, E357Q, L351D.
  • the binding agent comprises two polypeptide chains, wherein; one of the two polypeptide chains comprises a first dimerization domain (DDi) comprising a mutated CH3 domain comprising one or more amino acid substitutions at positions corresponding to D399, D/E356 and/or K370 in accordance with EU numbering, and; the other of the two polypeptide chains comprises a second dimerization domain (DD2) comprising a mutated CH3 domain comprising one or more amino acid substitutions at positions corresponding to D399, E357 and/or K439 in accordance with EU numbering.
  • DDi dimerization domain
  • DD2 second dimerization domain
  • the first dimerization domain (DDi) comprises a mutated CH3 domain comprising mutations D399N, D/E356Q and K370E in accordance with EU numbering
  • the second dimerization domain (DD2) comprises a mutated CH3 domain comprising mutations D399N, E357Q and K439E in accordance with EU numbering.
  • the first dimerization domain (DDi) and/or second dimerization domain (DD2) comprises a mutated CH3 domain further comprising amino acid substitutions at positions corresponding to Y349, T350, L351, P352 and/or S354 in accordance with EU numbering.
  • the first dimerization domain (DDi) comprises a mutated CH3 domain comprising mutations D399Q, D/E356Q, K370E, Y349K and S354K in accordance with EU numbering and wherein the second dimerization domain (DD2) comprises a mutated CH3 domain comprising mutations D399Q, E357Q, K439E, Y349D and S354D in accordance with EU numbering.
  • the first dimerization domain (DDi) comprises a mutated CH3 domain comprising mutations D399N, D/E356Q, K370E and L351W in accordance with EU numbering and wherein the second dimerization domain (DD2) comprises a mutated CH3 domain comprising mutations D399N, E357Q, K439E and L351R in accordance with EU numbering.
  • the first dimerization domain (DDi) comprises a mutated CH3 domain comprising mutations D399N, D/E356Q, K370E and S354M in accordance with EU numbering and wherein the second dimerization domain (DD2) comprises a mutated CH3 domain comprising mutations D399N, E357Q, K439E and L351Y in accordance with EU numbering.
  • the first dimerization domain (DDi) comprises a mutated CH3 domain comprising mutations D399N, D/E356Q, K370E and T350I in accordance with EU numbering and wherein the second dimerization domain (DD2) comprises a mutated CH3 domain comprising mutations D399N, E357Q, K439E and T350I in accordance with EU numbering.
  • the first dimerization domain (DDi) comprises a mutated CH3 domain comprising mutations D399N, D/E356Q, K370E and T350V in accordance with EU numbering and wherein the second dimerization domain (DD2) comprises a mutated CH3 domain comprising mutations D399N, E357Q, K439E and T350V in accordance with EU numbering.
  • the first dimerization domain (DDi) comprises a mutated CH3 domain comprising mutations D399N, D/E356Q, K370E and P352R in accordance with EU numbering and wherein the second dimerization domain (DD2) comprises a mutated CH3 domain comprising mutations D399N, E357Q, K439E and L351R in accordance with EU numbering.
  • the first dimerization domain (DDi) comprises a mutated CH3 domain comprising mutations D399N, D/E356Q, K370E and P352E in accordance with EU numbering and wherein the second dimerization domain (DD2) comprises a mutated CH3 domain comprising mutations D399N, E357Q, K439E and L351R in accordance with EU numbering.
  • binding agents may be composed of two different polypeptide chains that associates to from a dimer, herein referred as a heterodimer.
  • Heterodimers can be made by co-expressing two different polypeptide chains (e.g., Chain A and Chain B).
  • the polypeptide chain may comprise a dimerization domain comprising a wild type human CH2 and a mutated human CH3 that favorizes the formation of heterodimers.
  • the polypeptide chains have the possibility of forming a homodimer when expressed alone or to form a heterodimer (or mixture of homodimer and heterodimers) when expressed with a complementary chain.
  • Heterodimers were particularly made by transfection of a set of polypeptide chains comprising CH3 mutations (Chain A and Chain B exemplified Table 1). Table 1.
  • Exemplary embodiments of Chain A and Chain B (natural human IgGl CH2 and mutated IgGl CH3) Depending on the ratio of Chain A over Chain B, it is also possible to form homodimers upon co-expression of two such polypeptide chains.
  • co-expression of a polypeptide Chain A with polypeptide Chain B may therefore result in heterodimers of Chain A and Chain B, homodimers of Chain A, homodimers of Chain B and mixture thereof. It is also possible that residual monomers of Chain A and/or Chain B exist. Since the monomers, heterodimers and homodimers each contain antigen binding domains, each component of the mixture may have some level of activity.
  • monomers, heterodimers and homodimers that comprise the CH3 mutations disclosed herein as well as mixture of such monomers, heterodimers and/or homodimers are encompassed by the present disclosure.
  • polypeptide chains disclosed herein may comprise a mutated dimerization domain that comprises mutations known in the art to favorize heterodimer formation.
  • polypeptides chains of the present disclosure may comprise the configuration set forth in formula I, formula II, formula III, formula Ilia and formula Illb, formula IV, formula V, formula VI, formula VII or formula VIII disclosed herein and mutations known in the art to favorize heterodimer formation.
  • Knobs-into-holes first CH3 domain mutation T366Y and second CH3 domain mutation Y407T, first CH3 domain mutation T366W and second CH3 domain mutations T366S, L368A, Y407V, or first CH3 domain mutations S354C, T366W and second CH3 domain mutations Y349C, T366S,
  • L368A, Y407V L368A, Y407V
  • DD/KK mutations first CH3 domain mutations K409D, K392D, second CH3 domain mutations D399K, E356K
  • asymmetric re-engineering technology first CH3 domain mutations E356K, E357K, D399K and second CH3 domain mutations K439E, K370E , K409D
  • E236K, D278K XmAb mutations (first CH3 domain mutations S364H, F405A, second CH3 domain mutations Y349T, T394F), DuoBody mutations (first CH3 domain mutation F405L, second CH3 domain mutation K409R), Azymetric mutations (first CH3 domain mutations T350V,
  • the different modules of the polypeptide chains disclosed herein may be associated to each other via linkers.
  • the linkers used to join one or more modules of the polypeptide chain are not cleavable linkers.
  • the linker located immediately adjacent to the C-terminal end of the dimerization domain (Lc) does not comprise a cleavable linker.
  • At least one of the linkers located between two antigen binding domains do not comprise a cleavable linker.
  • linkers used to join one or more modules of the polypeptide chain may include non-cleavable linkers.
  • the linker located immediately adjacent to the C-terminal end of the dimerization domain is a non-cleavable linker.
  • At least one of the linkers located between two antigen binding domains is a non-cleavable linker.
  • the linker located immediately adjacent to the C- terminal end of the dimerization domain and the linker joining the first two antigen binding domains located at the C-terminal end of the dimerization domain are non-cleavable linkers.
  • the linker immediately adjacent to the N-terminal end of the dimerization domain may preferably comprise hinge region of an antibody.
  • the hinge region is natural hinge region.
  • the natural hinge region is a natural IgGl hinge region. In some embodiments, the natural hinge region is a natural human IgGl hinge region.
  • the natural hinge region is a natural IgG2 hinge region. In other embodiments, the natural hinge region is a natural human IgG2 hinge region.
  • the natural hinge region is a natural IgG3 hinge region. In other embodiments, the natural hinge region is a natural human IgG3 hinge region.
  • the natural hinge region is a natural IgG4 hinge region. In some embodiments, the natural hinge region is a natural human IgG4 hinge region.
  • the hinge region is a mutated hinge region.
  • the mutated hinge region is a mutated IgGl hinge region. In some embodiments, the mutated hinge region is a mutated human IgGl hinge region.
  • the mutated hinge region is a mutated IgG2 hinge region. In other embodiments, the mutated hinge region is a mutated human IgG2 hinge region.
  • the mutated hinge region is a mutated IgG3 hinge region. In other embodiments, the mutated hinge region is a mutated human IgG3 hinge region.
  • the mutated hinge region is a mutated IgG4 hinge region. In some embodiments, the mutated hinge region is a mutated human IgG4 hinge region.
  • all modules of the polypeptide chain are linked via non-cleavable linkers.
  • non-cleavable linkers include those that remains substantially intact during protein expression or during manufacturing process.
  • substantially intact means that linker cleavage occurs in 20% or less, in 15% or less, in 10% or less, in 7.5% or less, in 5% or less, in 4% or less, in 3% or less, in 2% or less, in 1% or less of the total polypeptide content of a given solution or composition.
  • non-cleavable linkers also include linkers that do not comprise a specific cleavage site for one or more proteases present in human or animal blood or serum.
  • non-cleavable linkers further include linkers that retain their integrity for at least one, two, three, four, five, six, twelve, twenty-four, forty-eight hours or more after administration upon administration of the binding agent in individuals.
  • a linker comprises both non-cleavable linkers and cleavable linkers.
  • a linker is not cleavable.
  • cleavable linkers may be used for in vivo release of drugs (e.g., cytostatic molecules, cytotoxic molecules, chemotherapeutics etc.) or labels attached to the polypeptide chain of the present disclosure.
  • drugs e.g., cytostatic molecules, cytotoxic molecules, chemotherapeutics etc.
  • cleavable linkers are provided for example in US2019/0010242 and include linkers that are sensitive to cleavage by a protease, usually an extracellular protease, such as a protease that is produced by a tumor or an activated immune effector cell and include those having a site for specific cleavage by proteases selected from ADAMS, ADAMTS, e g.
  • linkers include flexible linkers, rigid linkers, helical linkers and combination thereof.
  • Linkers are discussed for example, in Chen X et al. (Adv Drug Deliv Rev. 2013; 65(10): 1357-1369) the entire content of which is incorporated herein by reference.
  • a hinge region or a portion thereof may be used to link a module to the dimerization domain and is considered herein as a linker.
  • the hinge region may be derived from a natural antibody (of human or animal origin) or from a synthetic antibody. Hinge regions may be obtained, for example, from IgGs such as IgGl, IgG2, IgG3 or IgG4. Exemplary embodiments of hinge regions are provided in SEQ ID NO:98, SEQ ID NO: 121, SEQ ID NO: 125 and SEQ ID NO: 129.
  • the hinge region may have one or more amino acid substitutions, amino acid insertion and/or amino acid deletions in comparison with a natural hinge region.
  • Mutated hinge region includes, for example, a sequence that is from 80% to 99% identical with that of a natural IgGl, IgG2, IgG3 or IgG4 hinge region (mutated hinge region).
  • An exemplary and non-limiting embodiment of a mutated hinge region includes a hinge region of an IgG4 in which S228 is replaced with P (EU numbering) (Angal, S. et al., Mol Immunol 30, 105-108, 1993).
  • Other exemplary embodiments of mutated hinge are provided in SEQ ID NOs: 118-120, 122-124, 126-128 and 130- 132.
  • Flexible linkers are usually composed of small polar amino acids such as threonine or serine and glycine.
  • exemplary and non-limiting embodiments of flexible linkers include GS linkers (glycine/serine repeats) such as for example, (GGGS) n (GGGGS) m , (GS) n , (G4S) n , (GGS) n , (GGGS)n, (GGGGS)n, (GGSG) n , (GGGSS) n wherein n and m may be an integer such as 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10 or more, such as 15, 20 or 25.
  • flexible linkers include those comprising of consisting of the amino acid sequence set forth in SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103 or SEQ ID NO: 104.
  • SEQ ID NO: 104 may be represented by formula (GGGGS) n wherein n is an integer selected from 1 to 10 or alternatively by formula GGGGSXi wherein Xi is absent or, if present is from 1 to 9 repeats of amino acid residues 1 to 5 of SEQ ID NO: 104.
  • Rigid linkers of the present disclosure are usually composed of proline-rich sequences (XP) n , wherein X designate any amino acid, preferably Ala, Lys or Glu and n is an integer such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 etc. (Chen X et al. , 2013).
  • rigid linkers include those comprising of consisting of the amino acid sequence set forth in SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107 or SEQ ID NO: 108.
  • SEQ ID NO: 108 may be represented by formula (X(PAPAP)) n KA wherein n is an integer selected from 1 to 10, wherein X is present or absent and, if present, is A or, alternatively, SEQ ID NO: 108 may be represented by formula (XPAPAP)X2KA wherein X may be present or absent and, if present, is A; and wherein X2 is absent or, if present, is from 1 to 9 repeats of amino acid residues 1 to 6 of SEQ ID NO: 108.
  • Helical linkers may sometimes be characterized as rigid but are herein being separated into a distinct linker family. Exemplary embodiments of helical linkers are discussed in Chen X et al ., 2013 and comprise, for example, repeats of alanine residues flanked by a positively charged- and a negatively charged amino acid residue.
  • helical linkers include those comprising of consisting of the amino acid sequence set forth in SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111 and SEQ ID NO: 112.
  • SEQ ID NO: 112 may be represented by formula X(EAAAK) n X2 wherein n is an integer selected from 1 to 10, more preferably 2-5 wherein X and X2 are independently present or absent and, if present, is preferably A.
  • SEQ ID NO: 112 may be represented by formula X(EAAAK)X3X2, wherein X and X2 are independently present or absent and, if present, is preferably A; and X3 is absent or, if present, is from 1 to 9 repeats of amino acid residues 2 to 6 of SEQ ID NO: 112.
  • the linker immediately adjacent to the C-terminal end of the dimerization domain may comprise either a flexible linker, a rigid linker or a helical linker.
  • Linkers that may be particularly selected to occupy this position include for example and without limitations, a linker comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 100-109, SEQ ID NO:l l l or in SEQ ID NO: 112 wherein n is 1.
  • the linker joining the first two antigen binding domains located at the C-terminal end of the dimerization domain may comprise either a flexible linker, a rigid linker or a helical linker.
  • Linkers that may be particularly selected to occupy this position include for example and without limitations, a linker comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 100-110, or in SEQ ID NO:l 12 wherein n is 1.
  • the present disclosure also provides linkers having an addition of from 1 to 10 amino acids (and any range or value comprised within 1 and 10 such as for example, from 1 to 5) at one or both the N- or C-terminus of any of SEQ ID NOs: 100 to 112. These additional amino acid residues may each independently be selected from any amino acid residues. These additional amino acid residues preferably form a non-cleavable sequence.
  • the present disclosure also provides linkers having a deletion of from 1, 2, 3, 4 or 5 amino acids (and any value comprised within 1 and 5) at one or both the N- or C-terminus of any of SEQ ID NOs: 100 to 112.
  • Suitable linkers may comprise, for example, an amino acid sequence comprising from about 3 to about 50, from about 3 to about 40, from about 3 to about 30, from about 3 to about 25, from about 3 to about 20, from about 3 to about 15, from about 3 to about 10 amino acid residues.
  • each linker may independently range from about 5 to about 50 amino acid residues, including for example, from about 5 to about 40 amino acid residues, from about 10 to about 40 amino acid residues, from about 20 to about 40 amino acid residues, from about 20 to about 35 amino acid residues, from about 25 to about 30 amino acid residues and any sub-range comprised and including such ranges.
  • linkers that comprise the amino acid sequence set forth in SEQ ID NO: 104, SEQ ID NO: 108 or SEQ ID NO: 112 may have a “n” value preferably from 1 to 10, more preferably from 2-5 including 2, 3, 4 or 5.
  • Binding agents of the present disclosure encompass for example the antigen binding domains disclosed herein.
  • Binding agents of the present disclosure encompass for example the polypeptide chains disclosed herein.
  • Binding agents of the present disclosure encompass for example dimers of polypeptide chains disclosed herein.
  • Binding agents of the present disclosure encompass for example multimers of polypeptide chains disclosed herein.
  • Binding agents of the present disclosure may have a format of an antibody and antigen binding fragment thereof, an antibody -like molecule (Fc-, CH3- fusions and the like), a fusion with protein scaffolds, immune cell modulating agents and the like.
  • the binding agent comprises an antibody or an antigen binding fragment thereof.
  • the binding agent comprises an antibody-like molecule.
  • the binding agent may be fused with protein scaffold.
  • the binding agent comprises an immune cell modulating agent.
  • binding agents include antibodies and antigen-binding fragments thereof such as, for example and without limitations, single domain antibodies from camelids or sharks, human antibodies including IgGs (including human IgGl, human IgG2, human IgG3, human IgG4), human IgMs, human IgAs (including human IgAl and human IgA2), human IgEs, human IgDs, animal antibodies including for example, IgGs (IgGl, IgG2a, IgG2b, IgG2c, IgG3, IgG4), IgMs, IgAs, IgEs and IgDs.
  • human antibodies including IgGs (including human IgGl, human IgG2, human IgG3, human IgG4), human IgMs, human IgAs (including human IgAl and human IgA2), human IgEs, human IgDs, animal antibodies including for example, IgGs (IgGl, IgG2
  • binding agents include antigen-binding fragments such as, for example and without limitations, Fab, Fab’, F(ab’)2, complementarity determining regions, variable regions including VHs, VHHs, VLs, and the like.
  • Binding agents also include immune cell modulating agents such as for example, dual- affinity retargeting molecules (DARTs), chimeric antigen receptors (CAR) constructs, bispecific T cell engagers construct (BiTEs), bispecific killer cell engagers (BiKEs), trispecific killer cell engagers (TriKEs) containing scFvs or VHHs.
  • DARTs dual- affinity retargeting molecules
  • CAR chimeric antigen receptors
  • BiTEs bispecific T cell engagers construct
  • BiKEs bispecific killer cell engagers
  • TriKEs trispecific killer cell engagers
  • Binding agents also encompass fusion with protein scaffolds, including ankyrin repeat proteins, Z-domain of Staphylococcus protein-A, Type-III fibronetin, knottin and the like.
  • Exemplary embodiments of binding agents include monospecific-, bispecifics (symmetric or asymmetric) trispecific-, or multispecific antibodies as well as monovalent, bivalent, trivalent or multivalent antibodies, single chain FVs (scFVs) and derivatives such diabody, triabody, tetrabody, tandem di-scFvs, tandem tri-scFvs, scFV-Fc, minibody (scFV-CH3), tandem diabody, di-diabody, bibody and the like, VH or VHHs and derivatives such as, tandem bispecific or multispecific VHH, bivalent VHH-Fc fusions, VHH-hinge-CH2-CH3 fusions, bivalent CH3 fusions, VHH pentabody, decabody and the like.
  • the binding agents of the present disclosure may have a format as disclosed in PCT/CA2020/051753 filed on December 18, 2020 as formula la, formula lb, formula Ic, formula II, formula III, formula IV, formula V, formula VI, formula VII or formula VIII and the like or formula I, formula II, formula III, formula Ilia and formula Illb, formula IV, formula V, formula VI, formula VII or formula VIII disclosed herein.
  • the binding agents of the present disclosure may be formed by the assembly of two polypeptide chains having the same configuration (with same or different amino acid sequence) or having different configurations where the same or different configurations include the configuration set forth in formula I, formula II, formula III, formula Ilia and formula Illb, formula IV, formula V, formula VI, formula VII or formula VIII disclosed herein.
  • the binding agent of the present disclosure may comprise for example, one or more polypeptide chains independently comprising in aN- to C-terminal fashion an amino acid sequence of formula I: X-[(Aba)-(L b )] m-(DD)-[(Lc)-(Abd)] ceremoni - Y
  • n 0, 1, 2 or an integer greater than 2;
  • n 0, 1, 2 or an integer greater than 2;
  • Ab a , Ab d each represents an antigen binding domain wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1), an antigen binding domain 2 (ABD2) or an antigen binding domain 3 (ABD3);
  • X or Y are independently present or absent and comprises an amino acid sequence
  • L b , L c each independently comprises one or more linkers; and wherein DD represents a dimerization domain.
  • L b may be absent. In some embodiments L b 2 and/or L b 3 may be absent.
  • L c may be absent. In some embodiments, L ci , L C2 , and/or L C3 may be absent.
  • both L b and L c may be absent.
  • polypeptide chain comprises more than one antigen binding domains.
  • polypeptide chain comprises two antigen binding domains or more.
  • polypeptide chain comprises three antigen binding domains or more.
  • polypeptide chain comprises four antigen binding domains or more.
  • polypeptide chain comprises five antigen binding domains or more. In some embodiments the polypeptide chain comprises six antigen binding domains or more.
  • polypeptide chain comprises between one and twelve antigen binding domains.
  • the binding agent may comprise between one and twelve antigen binding domains, such as between one and two, between one and three, between one and four, between one and five, between one and six, between one and seven, between one and eight, between one and nine, between one and ten, between one and eleven, between one and twelve, between two and three, between two and four, between two and five, between two and six, between two and seven, between two and eight, between two and nine, between two and ten, between two and eleven, between two and twelve, between three and four, between three and five, between three and six, between three and seven, between three and eight, between three and nine, between three and ten, between three and eleven, between three and twelve, between four and five, between four and six, between four and seven, between four and eight, between four and nine, between four and ten, between four and eleven, between four and twelve, between five and six, between five and seven, between five and eight, between five and nine, between five and ten, between five and eleven, between five and twelve, between six and
  • the binding agent comprises one polypeptide chain.
  • the binding agent comprises two polypeptide chains.
  • the binding agent comprises three polypeptide chains.
  • the binding agent comprises four polypeptide chains.
  • the binding agent comprises five polypeptide chains.
  • the binding agent comprises six polypeptide chains. In some embodiments, the binding agent comprises seven polypeptide chains.
  • the binding agent comprises eight polypeptide chains.
  • the binding agent comprises nine polypeptide chains.
  • the binding agent comprises ten polypeptide chains.
  • the binding agent comprises more than ten polypeptide chains.
  • the binding agent comprises at least one polypeptide chain having formula II: X-(Ab ai )-(Lbi)-(DD)-(L ci )-(Abdi)-Y (formula II).
  • the binding agent comprises at least one polypeptide chain having formula III: X-(Ab ai )-(Lbi)-(DD)-(L ci )-(Abdi)-(L C 2)-(Abd2)-Y (formula III).
  • the binding agent comprises at least one polypeptide chain having formula IV: X-(Ab ai )-(Lb2)-(Ab a 2)-(Lbi)-(DD)-(L ci )-(Abdi)-Y (formula IV).
  • the binding agent comprises at least one polypeptide chain having formula V: X-(Ab ai )-(Lb2)-(Ab a 2)-(Lbi)-(DD)-(L ci )-(Abdi)-(L C 2)-(Abd2)-Y (formula V).
  • the binding agent comprises at least one polypeptide chain having formula VI: X-(Ab ai )-(Lb2)-(Ab a2 )-(Lbi)-(DD)-(L ci )-(Abdi)-(L C2 )-(Abd2)-(L C3 )-(Abd3)-Y (formula
  • the binding agent comprises at least one polypeptide chain having formula VII: X-(Ab ai )-(Lb3)-(Ab a2 )-(Lb2)-(Ab a3 )-(Lbi)-(DD)-(L ci )-(Abdi)-(L C2 )-(Abd2)-Y (formula
  • the binding agent comprises at least one polypeptide chain having formula VIII: X-(Ab ai )-(Lb3)-(Ab a2 )-(Lb2)-(Ab a3 )-(Lbi)-(DD)-(Lci)-(Abdi)-(Lc2)-(Abd2)-(Lc3)- (Abd3)-Y (formula VIII).
  • the binding agent comprises one or more polypeptide chains each independently comprising in aN- to C-terminal fashion an amino acid sequence of formula III
  • the binding agent comprises one or more polypeptide chains each independently comprising in N- to C-terminal fashion an amino acid sequence of formula III
  • the binding agent comprises one or more polypeptide chains each independently comprising in a N- to C-terminal fashion an amino acid sequence of formula III
  • the binding agent comprises one or more polypeptide chains each independently comprising in a N- to C-terminal fashion an amino acid sequence of formula III
  • the binding agent comprises one or more polypeptide chains each independently comprising in a N- to C-terminal fashion an amino acid sequence of formula III
  • the binding agent comprises one or more polypeptide chains each independently comprising in aN- to C-terminal fashion an amino acid sequence of formula III, wherein Ab ai is an antigen binding domain that binds to DR2, Ab di is an antigen binding domain that binds to PD-1 and Ab d 2 is an antigen binding domain that binds to CD47.
  • the binding agent comprises one or more polypeptide chains each independently comprising in aN- to C-terminal fashion an amino acid sequence of formula III, wherein Ab ai is an antigen binding domain that binds to DR2, Ab di is an antigen binding domain that binds to CD47 and Ab d 2 is an antigen binding domain that binds to PD-1.
  • the binding agent comprises one or more polypeptide chains each independently comprising in a N- to C-terminal fashion an amino acid sequence of formula Ilia:
  • the binding agent comprises one or more polypeptide chains each independently comprising in a N- to C-terminal fashion an amino acid sequence of formula Illb:
  • the binding agent comprises two identical polypeptide chains.
  • both polypeptide chains of the binding agent may have the configuration set forth in formula II (with same or different amino acid sequence).
  • both polypeptide chains of the binding agent may have the configuration set forth in formula III (with same or different amino acid sequence).
  • both polypeptide chains of the binding agent may have the configuration set forth in formula Ilia (with same or different amino acid sequence).
  • both polypeptide chains of the binding agent may have the configuration set forth in formula Illb (with same or different amino acid sequence).
  • one polypeptide chain may have the configuration set forth in formula Ilia
  • one polypeptide chain may have the configuration set forth in formula Illb (with antigen binding domains having same or different amino acid sequence).
  • one of the polypeptide chains may have the configuration set forth in formula II, while the other may have the configuration set forth in formula III.
  • one of the polypeptide chains may have the configuration set forth in formula II, while the other has the configuration set forth in formula IV. In some embodiments, one of the polypeptide chains may have the configuration set forth in formula III, while the other has the configuration set forth in formula IV.
  • one of the polypeptide chains may have the configuration set forth in formula IV, while the other has the configuration set forth in formula IV.
  • the binding agents of the present disclosure is monospecific or multispecific.
  • Monospecific binding agents encompass binding agents that are specific for a single epitope of a given antigen.
  • An exemplary embodiment of a monospecific binding agent includes a binding agent that comprise one antigen binding domain.
  • Another exemplary embodiment of a monospecific binding agent includes a binding agent that comprise more than one antigen binding domains, but the antigen binding domains have identical CDRs and framework regions.
  • Yet another exemplary embodiment of a binding agent chain includes a binding agent that comprise more than one antigen binding domains, but the antigen binding domains have identical CDRs and different framework regions.
  • a further exemplary embodiment of a monospecific binding agent includes a binding agent that comprise antigen binding domains that differ in the amino acid sequence of one or more of their CDRs (e.g., conservative substitution in one or more CDRs) without affecting their ability to bind to the same antigen or epitope.
  • Multispecific binding agents encompass binding agents that are specific for more than one epitope (of the same antigen or different antigens) or to more than one antigen.
  • a multipecific polypeptide chain or binding agent may thus have more than one antigen binding domains, at least two of which bind to different antigens or epitopes.
  • each antigen binding domain may be specific for a given antigen.
  • two or more antigen binding domains of a given binding agent may be specific for the same or different antigens.
  • three or more antigen binding domains of a given binding agent may be specific for the same or different antigens.
  • four or more antigen binding domains of a given binding agent may be specific for the same or different antigens.
  • five or more antigen binding domains of a given binding agent may be specific for the same or different antigens.
  • six or more antigen binding domains of a given binding agent may be specific for the same or different antigens.
  • the specificity may depend on the number of antigen binding domains present in a given binding agent.
  • Exemplary non-limiting embodiments of multispecific binding agent include those composed of multispecific polypeptide chains.
  • Other exemplary non-limiting embodiments of multispecific binding agent include those having two antigen binding domains of different specificities.
  • Yet other exemplary non-limiting embodiments of multispecific binding agent include those having more than two antigen binding domains that bind to two different antigens, proteins or to two different epitopes on the same antigens or proteins.
  • the binding agents of the present disclosure is monovalent or multivalent.
  • Exemplary non-limiting embodiments of multivalent binding agents include binding agents composed of multivalent polypeptide chains.
  • Other non-limiting exemplary embodiments of multivalent binding agent include binding agents composed of more than one monovalent polypeptide chain.
  • a bispecific binding agent may be bivalent or multivalent depending on the number of antigen binding domains that it contains.
  • Exemplary non limiting embodiments of bispecific binding agent include those comprising two identical bispecific polypeptide chains that form a dimer.
  • binding agent of the present disclosure may be monospecific.
  • the binding agent may comprise only one antigen binding domain.
  • the binding agent may comprise more than one identical antigen binding domains.
  • monospecific binding agents include the antigen binding domains disclosed herein including ABD1, ABD2, ABD3 or heavy chains disclosed herein.
  • the monospecific binding agents may comprise the antigen binding domains disclosed herein and a dimerization domain.
  • dimerization domains include without limitation a CH3 domain (including natural CH3 domain and natural human CH3 domain, mutated CH3 domain) may also include a CH2 domain (natural CH2 domain or mutated CH2 domain).
  • the dimerization domain is a Fc region of an antibody or a portion thereof.
  • the dimerization domain may also comprise a hinge region of an antibody or a portion thereof.
  • the hinge region or portion thereof is a human hinge region or a portion thereof.
  • the binding agent may comprise ABD1 and a dimerization domain.
  • the binding agent may comprise ABD2 and a dimerization domain.
  • the binding agent may comprise ABD3 and a dimerization domain.
  • the binding agent of the present disclosure may comprise a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:7 and a dimerization domain.
  • the binding agent of the present disclosure may comprise a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO: 14 and a dimerization domain.
  • the binding agent of the present disclosure may comprise a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:21 and a dimerization domain.
  • the binding agent of the present disclosure may comprise a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:28 and a dimerization domain. In some exemplary embodiments, the binding agent of the present disclosure may comprise a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:35 and a dimerization domain.
  • the binding agent of the present disclosure may comprise a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:42 and a dimerization domain.
  • the binding agent of the present disclosure may comprise a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:49 and a dimerization domain.
  • the binding agent of the present disclosure may comprise a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:56 and a dimerization domain.
  • the binding agent of the present disclosure may comprise a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:63 and a dimerization domain.
  • the binding agent of the present disclosure may comprise a heavy chain having an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:70 and a dimerization domain.
  • the binding agent of the present disclosure may comprise an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:71.
  • the binding agent of the present disclosure may comprise an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:72.
  • the binding agent of the present disclosure may comprise an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO: 73. In some exemplary embodiments, the binding agent of the present disclosure may comprise an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:74.
  • the binding agent of the present disclosure may comprise an amino acid sequence at least 75%, 80% 85%, 90%, 95% identical to the amino acid sequence set forth in SEQ ID NO:75.
  • binding agent of the present disclosure may be multispecific.
  • multispecific binding agents include are provided herein.
  • the binding agent may comprise more than one antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) as set forth herein and at least one of the antigen binding domains is an antigen binding domain that is capable of binding to an immune checkpoint protein.
  • ABS1 antigen binding domain 1
  • the binding agent may comprise more than one antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) as set forth herein, at least one of the antigen binding domains is an antigen binding domain that is capable of binding to an immune checkpoint protein and at least one of the antigen binding domains is an antigen binding domain that is capable of binding to a protein expressed at the surface of immune cells.
  • ABS1 antigen binding domain 1
  • the binding agent may comprise more than one antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) as set forth herein, at least one of the antigen binding domains is an antigen binding domain that is capable of binding to an immune checkpoint protein and at least one of the antigen binding domains is an antigen binding domain that is capable of binding to a protein expressed at the surface of tumors cells.
  • the binding agent comprises at least one antigen binding domain 1 (ABD1) and at least one antigen binding domain 2 (ABD2).
  • the binding agent comprises at least one antigen binding domain 1 (ABD1) and at least one antigen binding domain 3 (ABD3).
  • the binding agent comprises at least one antigen binding domain 2 (ABD2) and at least one antigen binding domain 3 (ABD3).
  • the binding agent comprises at least one antigen binding domain 1 (ABD1), at least one antigen binding domain 2 (ABD2) and at least one antigen binding domain 3 (ABD3).
  • the binding agent comprises one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:7, at least one of the antigen binding domains is an antigen binding domain 2 (ABD2) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 63 and at least one of the antigen binding domains is an antigen binding domain 3 (ABD3) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:70.
  • ABS1 antigen binding domain 1
  • ABS2 antigen binding domain 2
  • ABS3 antigen binding domain 3
  • the binding agent comprises one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 14, at least one of the antigen binding domains is an antigen binding domain 2 (ABD2) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 63 and at least one of the antigen binding domains is an antigen binding domain 3 (ABD3) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:70.
  • ABS1 antigen binding domain 1
  • ABS2 antigen binding domain 2
  • ABS3 antigen binding domain 3
  • the binding agent comprises one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:21, at least one of the antigen binding domains is an antigen binding domain 2 (ABD2) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 63 and at least one of the antigen binding domains is an antigen binding domain 3 (ABD3) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:70.
  • ABS1 antigen binding domain 1
  • ABS2 antigen binding domain 2
  • ABS3 antigen binding domain 3
  • the binding agent comprises one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:28, at least one of the antigen binding domains is an antigen binding domain 2 (ABD2) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 63 and at least one of the antigen binding domains is an antigen binding domain 3 (ABD3) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:70.
  • ABS1 antigen binding domain 1
  • ABS2 antigen binding domain 2
  • ABS3 antigen binding domain 3
  • the binding agent comprises one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:35, at least one of the antigen binding domains is an antigen binding domain 2 (ABD2) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 63 and at least one of the antigen binding domains is an antigen binding domain 3 (ABD3) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:70.
  • ABS1 antigen binding domain 1
  • ABS2 antigen binding domain 2
  • ABS3 antigen binding domain 3
  • the binding agent comprises one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:42, at least one of the antigen binding domains is an antigen binding domain 2 (ABD2) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 63 and at least one of the antigen binding domains is an antigen binding domain 3 (ABD3) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:70.
  • ABS1 antigen binding domain 1
  • ABS2 antigen binding domain 2
  • ABS3 antigen binding domain 3
  • the binding agent comprises one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:49, at least one of the antigen binding domains is an antigen binding domain 2 (ABD2) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 63 and at least one of the antigen binding domains is an antigen binding domain 3 (ABD3) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:70.
  • ABS1 antigen binding domain 1
  • ABS2 antigen binding domain 2
  • ABS3 antigen binding domain 3
  • the binding agent comprises one or more antigen binding domains, wherein at least one of the antigen binding domains is an antigen binding domain 1 (ABD1) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:56, at least one of the antigen binding domains is an antigen binding domain 2 (ABD2) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 63 and at least one of the antigen binding domains is an antigen binding domain 3 (ABD3) and comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO:70.
  • ABS1 antigen binding domain 1
  • ABS2 antigen binding domain 2
  • ABS3 antigen binding domain 3
  • the binding agent comprises one or more polypeptide chains, wherein at least one of the polypeptide chains has an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:77.
  • the binding agent comprises one polypeptide chain that has the amino acid sequence set forth in SEQ ID NO:77.
  • the binding agent comprises two polypeptide chains, having an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:77.
  • the binding agent comprises two polypeptide chains that have the amino acid sequence set forth in SEQ ID NO:77.
  • the binding agent comprises one or more polypeptide chains, wherein at least one of the polypeptide chains has an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:78.
  • the binding agent comprises one polypeptide chain that has the amino acid sequence set forth in SEQ ID NO:78.
  • the binding agent comprises two polypeptide chains, having an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:78.
  • the binding agent comprises two polypeptide chains that have the amino acid sequence set forth in SEQ ID NO:78.
  • the binding agent comprises one or more polypeptide chains, wherein at least one of the polypeptide chains has an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:79.
  • the binding agent comprises one polypeptide chain that has the amino acid sequence set forth in SEQ ID NO:79.
  • the binding agent comprises two polypeptide chains, having an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:79.
  • the binding agent comprises two polypeptide chains that have the amino acid sequence set forth in SEQ ID NO:79.
  • the binding agent comprises one or more polypeptide chains, wherein at least one of the polypeptide chains has an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:80.
  • the binding agent comprises one polypeptide chain that has the amino acid sequence set forth in SEQ ID NO:80.
  • the binding agent comprises two polypeptide chains, having an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:80.
  • the binding agent comprises two polypeptide chains that have the amino acid sequence set forth in SEQ ID NO:80.
  • the binding agent comprises one or more polypeptide chains, wherein at least one of the polypeptide chains has an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:81.
  • the binding agent comprises one polypeptide chain that has the amino acid sequence set forth in SEQ ID NO:81.
  • the binding agent comprises two polypeptide chains, having an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:81.
  • the binding agent comprises two polypeptide chains that have the amino acid sequence set forth in SEQ ID NO:81.
  • the binding agent comprises one or more polypeptide chains, wherein at least one of the polypeptide chains has an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:82.
  • the binding agent comprises one polypeptide chain that has the amino acid sequence set forth in SEQ ID NO:82.
  • the binding agent comprises two polypeptide chains, having an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:82.
  • the binding agent comprises two polypeptide chains that have the amino acid sequence set forth in SEQ ID NO:82.
  • the binding agent comprises one or more polypeptide chains, wherein at least one of the polypeptide chains has an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 83.
  • the binding agent comprises one polypeptide chain that has the amino acid sequence set forth in SEQ ID NO:83.
  • the binding agent comprises two polypeptide chains, having an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO: 83.
  • the binding agent comprises two polypeptide chains that have the amino acid sequence set forth in SEQ ID NO:83.
  • the binding agent comprises one or more polypeptide chains, wherein at least one of the polypeptide chains has an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:85.
  • the binding agent comprises one polypeptide chain that has the amino acid sequence set forth in SEQ ID NO:85.
  • the binding agent comprises two polypeptide chains, having an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:85.
  • the binding agent comprises two polypeptide chains that have the amino acid sequence set forth in SEQ ID NO:85.
  • the binding agent comprises one or more polypeptide chains, wherein at least one of the polypeptide chains has an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:86.
  • the binding agent comprises one polypeptide chain that has the amino acid sequence set forth in SEQ ID NO:86.
  • the binding agent comprises two polypeptide chains, having an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:86.
  • the binding agent comprises two polypeptide chains that have the amino acid sequence set forth in SEQ ID NO:86.
  • the binding agent comprises one or more polypeptide chains, wherein at least one of the polypeptide chains has an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:87.
  • the binding agent comprises one polypeptide chain that has the amino acid sequence set forth in SEQ ID NO:87.
  • the binding agent comprises two polypeptide chains, having an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:87.
  • the binding agent comprises two polypeptide chains that have the amino acid sequence set forth in SEQ ID NO:87.
  • the binding agent comprises one or more polypeptide chains, wherein at least one of the polypeptide chains has an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:88.
  • the binding agent comprises one polypeptide chain that has the amino acid sequence set forth in SEQ ID NO:88.
  • the binding agent comprises two polypeptide chains, having an amino acid sequence at least 75%, 80% 85%, 90%, 95%, 99% or 100% identical to the amino acid sequence set forth in SEQ ID NO:88.
  • the binding agent comprises two polypeptide chains that have the amino acid sequence set forth in SEQ ID NO:88.
  • the binding agent of the present disclosure comprises an antigen binding domain that binds DR2, an antigen binding domain that binds PD 1 and an antigen binding domain that binds to CD47.
  • the binding agent of the present disclosure may be capable of bringing T cells in proximity to DR2-expressing tumor cells, may be capable of restoring T cell function and/or may be capable of enhancing macrophage function via blocking of SIRPa/CD47 interaction.
  • the binding agent may exhert its anti-tumor activity via antibody-dependent cell-mediated cellular cytotoxicity (ADCC).
  • ADCC antibody-dependent cell-mediated cellular cytotoxicity
  • Variants of the sequences disclosed herein are also encompassed by the present disclosure.
  • Variants encompassed by the present disclosure include those which may comprise an insertion of one or more amino acid residues at one or more position, a deletion of one or more amino acid residues at one or more position or a substitution of one or more amino acid residues at one or more position (conservative or non-conservative substitutions).
  • Naturally occurring residues are divided into groups based on common side chain properties.
  • Conservative substitutions may be made by exchanging an amino acid from one of the groups listed below (group 1 to 6) for another amino acid of the same group.
  • Non conservative substitutions will entail exchanging a member of one of these groups for another.
  • Amino acids can be categorized based on net charge as indicated by an amino acid’s isoelectric point.
  • the isoelectric point is the pH at which the average net charge of the amino acid molecule is zero. When pH>pI, an amino acid has a net negative charge, and when the pH ⁇ pI, an amino acid has a net positive charge.
  • the measured pi value for an antibody is between about 3 and 9 (e.g.
  • the measured pi value for an antibody is between about 4 and 7 (e.g. 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0), and any values in between.
  • Exemplary isoelectric points of amino acids are shown in Table 2 below.
  • amino acids with positive electrically charged side chains include, for example, Arginine (R), Histidine (H), and Lysine (K).
  • Amino acids with negative electrically charged side chains include, for example, Aspartic Acid (D) and Glutamic Acid (E).
  • Amino acids with polar properties include, for example, Serine (S), Threonine (T), Asparagine (N), Glutamine (Q), and Cysteine (C), Tyrosine (Y) and Tryptophan (W).
  • Non-polar amino acids include, for example, Alanine (A), Valine (V), Isoleucine (I), Leucine (L), Methionine (M), Phenylalanine (F), Glycine (G) and Proline (P).
  • the isoelectric point of an antibody is modified via amino acid substitution. See , e.g. US20110076275.
  • modifying the isoelectric point of a polypeptide comprising an antibody results in a change in the antibody’s half-life.
  • the degree of similarity and identity between variable chains is determined herein using the Blast2 sequence program (Tatiana A. Tatusova, Thomas L. Madden (1999), "Blast 2 sequences - a new tool for comparing protein and nucleotide sequences", FEMS Microbiol Lett. 174:247-250) using default settings, i.e., blastp program, BLOSUM62 matrix (open gap 11 and extension gap penalty 1; gapx dropoff 50, expect 10.0, word size 3) and activated filters.
  • Blast2 sequence program Tropiana A. Tatusova, Thomas L. Madden (1999), "Blast 2 sequences - a new tool for comparing protein and nucleotide sequences", FEMS Microbiol Lett. 174:247-250
  • blastp program BLOSUM62 matrix (open gap 11 and extension gap penalty 1; gapx dropoff 50, expect 10.0, word size 3) and activated filters.
  • Percent identity will therefore be indicative of amino acids which are identical in comparison with the original peptide and which may occupy the same or similar position.
  • Percent similarity will be indicative of amino acids which are identical and those which are replaced with conservative amino acid substitution in comparison with the original peptide at the same or similar position.
  • Variants of the present disclosure may therefore comprise a sequence that is at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical with that of an original or reference sequence or a portion of an original sequence.
  • polypeptide chains having an amino acid sequence which is at least 75%, 80% 85%, 90%, 95%, 99% identical or less than 100% identical to a given amino acid sequence may have amino acid substitutions, additions or deletions that are generally located outside of the complementarity determining regions.
  • a variant may have at least 80% sequence identity with a sequence disclosed herein.
  • a variant may have at least 85% sequence identity with a sequence disclosed herein.
  • a variant may have at least 90% sequence identity with a sequence disclosed herein.
  • a variant may have at least 95% sequence identity with a sequence disclosed herein.
  • a variant may have at least 99% sequence identity with a sequence disclosed herein.
  • variants include polypeptide chains or binding agents that comprise a hinge, Fc, CH3, CH2/CH3 region that is derived from a natural antibody but that comprise one, two, three, four, five, six, seven, eight, nine, ten or more amino acid difference (including amino acid substitutions, insertions or deletions).
  • the polypeptide chain of the present disclosure may thus comprise a mutated hinge region that is at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 99% identical to a hinge region of a natural antibody.
  • the polypeptide chain of the present disclosure may thus comprise a mutated Fc portion that is at least 80% identical to a Fc of a natural antibody.
  • the polypeptide chain of the present disclosure may thus comprise a mutated CH2 domain that is at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 99% identical to the CH2 domain of a natural antibody.
  • the polypeptide chain of the present disclosure may thus comprise a mutated CH3 domain that is at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 99% identical to the CH3 domain of a natural antibody.
  • the polypeptide chain of the present disclosure may thus comprise a mutated CH2/CH3 domain that is at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 99% identical to the CH2/CH3 domain of a natural antibody.
  • Nucleic acid molecules of the present disclosure may be single-stranded or double- stranded.
  • the nucleic acid molecules disclosed herein may comprises deoxyribonucleotides, ribonucleotides, modified deoxyribonucleotides or modified ribonucleotides.
  • the nucleic acid molecules of the present disclosure may comprise for example DNA.
  • DNA segments and vectors encoding one or more modules or entire polypeptide chains are particularly provided.
  • the DNA segments and/or vectors may be provided in separate vials and sold as a kit.
  • DNA segments that comprise sequence allowing directional assembly of the modules and cloning vectors that incorporate the DNA segments or entire polypeptide chains.
  • the DNA segments and vectors may be provided as part of a kit for assembling DNA constructs capable of expressing the polypeptide chains or binding agents disclosed herein.
  • the kit may at least comprise one or more DNA segment or vectors that allow a user to generate a polypeptide chain comprising the mutated dimerization domain having amino acid substitutions at position 356, 357, 370, 399 and/or 439 (in accordance with EU numbering system) as disclosed herein.
  • DNA sequences that encode the same, substantially the same or a functionally equivalent amino acid sequence may be produced and used.
  • the nucleotide sequences of the present disclosure may be engineered using methods generally known in the art in order to alter the nucleotide sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product.
  • DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences.
  • oligonucleotide- mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth. Codon-optimized nucleic acids encoding the polypeptide chains described herein are encompassed by the present disclosure.
  • polypeptide chains and binding agents disclosed herein may be made by a variety of methods familiar to those skilled in the art, including by recombinant DNA methods or by in vitro transcription/translation.
  • the polypeptide chains described herein are expressed from nucleic acid sequences inserted into an expression vector, /. e. , a vector that contains the elements for transcriptional and translational control of the inserted coding sequence in a particular host. These elements may include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' un-translated regions.
  • a variety of expression vector/host cell systems known to those of skill in the art may be used to express the polypeptide chains described herein.
  • each of such polypeptide chain may be provided by separate expression vectors or by a unique expression vector.
  • the two chains of a binding agent may be encoded by a single vector or by separate vectors (vector set).
  • Polypeptides are often expressed in mammalian cells.
  • a stable expression system may be used in which the DNA segment is incorporated into the host cell genome or maintained in an episomal form by the use of selectable markers.
  • a host cell type may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed polypeptide in the desired fashion.
  • Different host cells that have specific cellular machinery and characteristic mechanisms for post-translational activities e.g., CHO, HeLa, MDCK, HEK293, and W138
  • ATCC American Type Culture Collection
  • microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with baculovirus vectors; plant cell systems transformed with viral or bacterial expression vectors; or animal cell systems.
  • the present disclosure therefore relates to isolated cells transformed or transfected with a vector, nucleic acid, sets of vectors or sets of nucleic acids encoding at least one of the polypeptide chains described herein.
  • the present disclosure therefore also relates to isolated cells capable or expressing the polypeptide chains or binding agents disclosed herein.
  • the present disclosure also relates to a method of making binding agents.
  • the method may comprise providing a cell (e.g., a mammalian cell) with a vector or sets of vectors encoding one or more of the polypeptide chains disclosed herein and allowing expression.
  • a cell e.g., a mammalian cell
  • the method may also comprises purifying the binding agent from cells or cell debris.
  • the method of manufacture allows to reach a purity level of at least 80%, of at least 85%, at least 90%, at least 99% (of dimers).
  • the purity level of the binding agent is between 80.0% to 99.9%.
  • the purity level of the binding agent is between 95.0% to 99.9%.
  • the purity level of the binding agent is at least 90.0 +/- 5.0%.
  • the purity level of the binding agent is at least 95.0 +/- 5.0%.
  • the purity level of the binding agent equal to or higher than 95 %.
  • the purity level of the binding agent is 97.0 +/- 1.0%.
  • the purity level of the binding agent equal to or higher than 97 %.
  • the purity level of the binding agent is 99.0 +/- 1.0%.
  • the purity level of the binding agent equal to or higher than 99 %.
  • the titer of the binding agents produced by cells may be 0.1 g/L or more. In some instances, the titer of the binding agents produced by cells may be 0.5 g/L or more. In some instances, the titer of the binding agent produced by cells may be 1 g/L or more. In some instances, the titer of the binding agent produced by cells may be 2 g/L or more. In some instances, the titer of the binding agent produced by cells may be 3 g/L or more. In some instances, the titer of the binding agent produced by cells may be 4 g/L or more. In some instances, the titer of the binding agent produced by cells may be 5 g/L or more.
  • the titer of the binding agent produced by cells may be 6 g/L or more.
  • homodimers are made by transfection of cells with a vector comprising a nucleic acid sequence encoding one of the polypeptide chains disclosed herein.
  • the collected supernatant may contain homodimers or a mixture of monomers and/or homodimers.
  • heterodimers are made by co-transfection of cells with at least two types of vectors (a vector set) each comprising a nucleic acid sequence encoding two distinct polypeptide chains.
  • the proper ratio of Chain A over Chain B is generally dependent on the level of protein expression obtained from each individual plasmid and may vary for example from about 1:10 to about 10:1. A DNA ratio of approximately 1:1 is particularly preferred for some of the constructs disclosed herein.
  • Heterodimers can also be made by transfecting cells with a single vector encoding both polypeptide chains. The collected supernatant may contain heterodimers or a mixture of monomers, heterodimers and/or homodimers.
  • the method of making polypeptide chains of the present disclosure may further comprise a step of separating or isolating monomers, homodimers and heterodimers from a mixture that comprises.
  • Homodimers or heterodimers may be purified and isolated, for example, by size exclusion chromatography or with the help of tags or by other methods known to a person of skill in the art.
  • the method may also comprise a step of isolating and/or purifying the binding agent from impurities.
  • compositions comprising homodimers, heterodimers or a mixture of monomers heterodimers and/or homodimers.
  • the composition may mainly comprise homodimers.
  • the composition may comprise a proportion of at least about 80%, at least 85%, at least 90%, at least 99% or 100% of homodimers.
  • the composition may mainly comprise heterodimers.
  • the composition may comprise a proportion of at least about 80%, at least 85%, at least 90%, at least 99% or 100% of heterodimers.
  • polypeptide chain or binding agent of the present disclosure may be conjugated, for example, with a therapeutic moiety (for therapeutic purposes) or with a detectable moiety (i.e., for detection or diagnostic purposes) or to a protein allowing an extended half-life or is attached to nanoparticle.
  • therapeutic or detectable moieties may be linked to at least one amino acid residues of the polypeptide chain.
  • the polypeptide chain or binding agent of the present disclosure is conjugated with a therapeutic moiety such as for example and without limitation, a chemotherapeutic, a cytokine, a cytotoxic agent, an anti-cancer drug (e.g., small molecule), and the like.
  • a therapeutic moiety such as for example and without limitation, a chemotherapeutic, a cytokine, a cytotoxic agent, an anti-cancer drug (e.g., small molecule), and the like.
  • Therapeutic moiety may include, for example and without limitation, Yttrium-90, Scandium-47, Rhenium-186, Iodine-131, Iodine-125, and many others recognized by those skilled in the art (e.g., lutetium (e.g., Lu 177 ), bismuth (e.g., Bi 213 ), copper (e.g., Cu 67 )), 5-fluorouracil, adriamycin, irinotecan, taxanes, pseudomonas endotoxin, ricin, auristatins (e.g., monomethyl auristatin E, monomethyl auristatin F), maytansinoids (e.g., mertansine) and other toxins.
  • lutetium e.g., Lu 177
  • bismuth e.g., Bi 213
  • copper e.g., Cu 67
  • 5-fluorouracil e.g., 5-fluor
  • the polypeptide chain or binding agent of the present disclosure is conjugated with a detectable moiety including for example and without limitation, a moiety detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical and/or other physical means.
  • a detectable moiety may be coupled either directly and/or indirectly (for example via a linkage, such as, without limitation, a DOTA or NHS linkage) to the polypeptide chain or binding agent using methods well known in the art.
  • a linkage such as, without limitation, a DOTA or NHS linkage
  • a wide variety of detectable moieties may be used, with the choice depending on the sensitivity required, ease of conjugation, stability requirements and available instrumentation.
  • a suitable detectable moiety includes, but is not limited to, a fluorescent label, a radioactive label (for example, without limitation, 125 I, In 111 , Tc", I 131 and including positron emitting isotopes for PET scanner etc), a nuclear magnetic resonance active label, a luminescent label, a chemiluminescent label, a chromophore label, an enzyme label (for example and without limitation horseradish peroxidase, alkaline phosphatase, etc.), quantum dots and/or a nanoparticle.
  • Detectable moiety may cause and/or produce a detectable signal thereby allowing for a signal from the detectable moiety to be detected.
  • compositions comprising the polypeptide chains or binding agents of the present disclosure are also encompassed by the present disclosure.
  • the pharmaceutical composition may also comprise a pharmaceutically acceptable carrier.
  • the pharmaceutical composition comprises conjugated polypeptide chains or conjugated binding agent as disclosed herein. In some embodiments, the pharmaceutical composition comprises polypeptide chains or binding agents conjugated with a therapeutic moiety. In some embodiments, the pharmaceutical composition comprises polypeptide chains or binding agent is conjugated with a detectable label.
  • a pharmaceutical composition may contain pharmaceutically acceptable carriers comprising water, PBS, salt solutions, gelatins, oils, alcohols, and other excipients and auxiliaries that facilitate processing of the active compounds into preparations that may be used pharmaceutically. In other instances, such preparations may be sterilized.
  • compositions means therapeutically effective amounts of the agent together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvant and/or carriers.
  • a “therapeutically effective amount” as used herein refers to that amount which provides a therapeutic effect for a given condition and administration regimen.
  • Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HCL, acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts).
  • Solubilizing agents e.g., glycerol, polyethylene glycerol
  • anti oxidants e.g., ascorbic acid, sodium metabi sulfite
  • preservatives e.g., thimerosal, benzyl alcohol, parabens
  • bulking substances or tonicity modifiers e.g., lactose, mannitol
  • covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts.
  • Controlled or sustained release compositions include formulation in lipophilic depots (e.g., fatty acids, waxes, oils). Also encompassed by the disclosure are particulate compositions coated with polymers (e.g., poloxamers or poloxamines). Other embodiments of the compositions of the disclosure incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal, oral, vaginal, rectal routes.
  • the pharmaceutical composition is administered parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitonealy, intraventricularly, intracranially and intratumorally.
  • pharmaceutically acceptable carrier or “pharmaceutical carrier” are known in the art and include, but are not limited to, 0.01-0.1 M or 0.05 M phosphate buffer or 0.8 % saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non- aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's orfixed oils.
  • Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, collating agents, inert gases and the like.
  • the therapeutically effective dose may be estimated initially either in cell culture assays or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the concentration range and route of administration. Such information may then be used to determine useful doses and routes for administration in humans. These techniques are well known to one skilled in the art and a therapeutically effective dose refers to that amount of active ingredient that ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating and contrasting the ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population) statistics. Any of the pharmaceutical compositions described above may be applied to any subject in need of therapy, including, but not limited to, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and especially humans.
  • the pharmaceutical compositions described herein may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.
  • the pharmaceutical composition is made of binding agents that have a purity level of between 80.0% to 99.9%.
  • the pharmaceutical composition comprises binding agents that are substantially free of impurities.
  • pharmaceutical composition comprises binding agents that are at least 90.0 +/- 5.0% pure.
  • the pharmaceutical composition comprises binding agents that are at least 95.0 +/- 5.0% pure.
  • the pharmaceutical composition comprises binding agent that are at least 99.0 +/- 1.0% pure.
  • the pharmaceutical composition comprises binding agents that are stable in solution under one or more stress conditions as described herein.
  • polypeptide chains and binding agents of the present disclosure may be used for treatment of disorders or diseases.
  • the polypeptide chains and binding agents may be used to target therapeutics and/or diagnostics to a target cell, circulating protein or tissue.
  • polypeptide chains and binding agents may be conjugated with a therapeutic moiety and used for therapeutic methods.
  • polypeptide chains and binding agents may be conjugated with a detectable moiety and used for detection or diagnostic methods.
  • polypeptide chains and binding agents of the present disclosure may be used for targeting tumors in vivo.
  • the polypeptide chains and binding agents are used for promoting tumor regression and/or reducing tumor volume in vivo.
  • polypeptide chains and binding agents of the present disclosure may thus be used for cancer treatment.
  • the method of the present disclosure may comprise a step of administering the polypeptide chains, binding agents or mixture disclosed herein or a pharmaceutical composition comprising the polypeptide chains, binding agents or mixture to an individual in need.
  • the polypeptide chains and binding agents are administered in combination with a chemotherapeutic.
  • the individual in need may be a human. Further in accordance with the present disclosure, the individual in need may be an animal. In some embodiment, treatment of disorders or diseases that are caused or associated with expression of a neo-antigen are particularly contemplated.
  • treatment of disorders or diseases that are caused or associated with expression over expression of an antigen are particularly contemplated.
  • the disorder or disease may be cancer.
  • the disorder or disease may be an infection.
  • the disorder or disease may be an immune dysregulation.
  • the disorder or disease may be a metabolic dysregulation.
  • the binding agent is administered intravenously.
  • the binding agent is administered by infusion.
  • polypeptide chains and binding agents of the present disclosure may be used for detection purposes.
  • Detection of a particular target may be performed in vitro by contacting a sample, containing or suspected of containing the target with a polypeptide chain or binding agent comprising an antigen binding domain for such target and quantifying a signal associated with positive or negative binding using a detection apparatus.
  • the sample may originate from a mammal (e.g., a human).
  • the sample may be a tissue sample obtained from the mammal or a cell culture supernatant.
  • the sample may be a serum sample, a plasma sample, a blood sample, semen or ascitic fluid obtained from the mammal.
  • Detection of a particular target may be performed in vivo by administering a polypeptide chain or binding agent comprising an antigen binding domain for such target to an individual and quantifying a signal associated with positive or negative binding using a detection apparatus.
  • a drug e.g., antibody, small molecule, a polypeptide chain or binding agent disclosed herein
  • a drug e.g., antibody, small molecule, a polypeptide chain or binding agent disclosed herein
  • the following non-limiting embodiments are particularly contemplated.
  • Table 3 Table 4, Table 5 and Table 6 illustrate VHHs having biological activity on their own (e.g., as fusion with dimerization domain) and as part of the multimeric, multivalent and/or multispecific binding agents as exemplified in Table 7.
  • Single domain antibodies were generated by immunizing alpacas ( Vicugna pacos) or llamas ⁇ llama glama ) with human antigens, cDNA plasmid encoding the human antigens and/or cells overexpressing the human antigens.
  • anti-DR2 single domain antibodies were generated by immunizing alpacas ⁇ Vicugna pacos) with DR2 antigens including the human DR2 protein, human DR2 cDNA plasmid, and human DR2 overexpressing cell line; SH-SY5Y-D2 cells.
  • Anti-PD-1 single domain antibodies were generated by immunizing alpacas ⁇ Vicugna pacos) with PD-1 antigens including the human PD-1 protein, human PD-1 cDNA plasmid and a human PD-1 overexpressing cell line; CHO-PD1 cells.
  • anti-CD47 single domain antibodies were generated by immunizing llamas ⁇ llama glama) with CD47 antigens including the human CD47 protein, human CD47 cDNA, and human PBMCs (activated).
  • DNA fragments encoding VHHs were generally subcloned into into constructs for expression of polypeptide chains (e.g., see Table 6 or Table 7) and in vitro and in vivo testing.
  • Controls were also generated by substitution of one or more VHH with HEWL-specific
  • Example 2- Transfection, expression, and purification of binding agents Transfection and expression of polypeptide chains in ExpiCHO or in Expi293 cells
  • Protein dimers e.g., homodimers or heterodimers were expressed in 2.5 mL or 400 mL culture volume from the DNA construct using the ExpiCHOTM Expression System (Thermo Fisher, Cat. No. A29133) or the Expi293TM Expression System (Thermo Fisher, Cat. No. A14635).
  • CHO cells were allowed to recover in culture for two or more passages before transfection. Cells were then passaged every 3-4 days until they reach 4xl0 6 -6xl0 6 cells/mL at which time they were diluted to 2xl0 5 -3xl0 5 cells/mL in ExpiCHOTM Expression Medium pre-warmed to 37 ° C. The day prior to transfection, cells were diluted to 3 xlO 6 - 4xl0 6 cells/mL, and on the day of transfection, cells were further diluted to 6.xl0 6 cells/mL.
  • ExpiCHOTM feed (0.6 mL for 2.5 mL of culture volume; 96 mL for 400 mL of culture volume) and ExpiCHOTM enhancer (15 ⁇ L for 2.5 mL of culture volume; 2.4 mL for 400 mL of culture volume) were added to the cells.
  • the cells were returned to INFORS HT incubator set at 37 ° C under 8% CO2 and 80% humidity with shaking at 125 rpm (25mm orbit). 8 days post-transfection, supernatants were clarified by centrifugation at 4000 x g for 30 minutes.
  • Supernatants were filter-sterilized using a NalgeneTM Rapid-FlowTM Sterile Disposable Filter Units 1000 mL filter unit (Thermo Scientific, Cat. No. 567-0020) and were stored at 4 ° C or frozen for later analysis.
  • Freshly thawed HEK293 cells were allowed to recover in culture for two or more passages before transfection. Cells were then passaged every 3-4 days until they reach 3xl0 6 -5xl0 6 cells/mL at which time they were diluted to 3xl0 5 -5xl0 5 cells/mL in Expi293TM Expression Medium pre warmed to 37 ° C. The day prior to transfection, cells were diluted to 2.5xl0 6 -3xl0 6 and on the day of transfection, cells were further diluted to 3xl0 6 viable cells/ mL.
  • Opti-MEMTM I Reduced Serum medium 1 pg of DNA / mL of culture volume was diluted with Opti-MEMTM I Reduced Serum medium to get a final volume of 150 ⁇ L for 2.5 mL of culture volume and 24 mL for 400 mL of culture volume.
  • ExpiFectamineTM 293 Reagent 8 ⁇ L for 2.5 mL of culture volume; 1.3 mL for 400 mL of culture volume) was added to medium Opti-MEMTM I reduced serum medium (140 ⁇ L for 2.5 mL of culture volume; 22.5 mL for 400 mL of culture volume) to incubate at room temperature for 5 minutes.
  • Diluted ExpiFectamineTM was added to diluted DNA and incubate for 15 minutes at room temperature.
  • ExpiFectamineTM/ DNA solution was transferred to culture drop by drop (at 3xl0 6 cells/mL) while swirling. The cells were incubated at 37 ° C under 8% CO2 and 80% humidity with overnight shaking (INFORS HT shaker, 125 rpm). 18-22h after onset of transfection, ExpiFectamineTM 293 Transfection Enhancer 1 (15 ⁇ L for 2.5 mL of culture volume; 2.4 mL for 400 mL of culture volume) and ExpiFectamineTM 293 Transfection Enhancer 2 (50 ⁇ L for 2.5 mL of culture volume; 24 mL for 400 mL of culture volume) were added to the cells.
  • the cells were returned to INFORS HT incubator set at 37 ° C under 8% CO2 and 80% humidity with shaking at 125 rpm (25mm orbit). 5 days post-transfection, supernatants were clarified by centrifugation at 4000 x g for 30 minutes. Supernatants were filter-sterilized using a NalgeneTM Rapid-FlowTM Sterile Disposable Filter Units 1000 mL filter unit (Thermo Scientific, Cat. No. 567-0020) and were stored at 4 ° C or frozen for later analysis.
  • Proteins are purified using 3-mL MabSelectTM SuReTM resin (GE Healthcare, Cat. No. 17- 5438-02) with gravity columns or 40-mL MabSelectTM SuReTM resin with AKTA PURE (GE Healthcare, Piscataway, NJ) depending on the supernatant volume. Resin was incubated with 0.5 M NaOH overnight and equilibrated with Tris-base buffer pH 7.4 (50 mM Tris-HCl, 150 mM NaCl, pH 7.4) prior to injection. Supernatant was applied on gravity columns or the at 5 mL/min on 40-mL column.
  • Resin column was washed with 3 CV (column volume) with Tris-base buffer pH 7.4 at a flow rate of 10 mL/min. Protein was eluted with 3 CV of 0.1 M citrate acid pH 3 at 10 mL/min. Fractions identified with protein from the visual output of the chromatogram (absorbance at 280 nm) were pooled together.
  • Buffer exchange was carried out by sample concentrators for proteins purified from gravity columns or either by dialysis or by desalting column for proteins purified from AKTA PURE. Proteins purified from gravity columns were concentrated with sample concentrator VivaSpin 2, 50 kDa MWCO (GE Healthcare, Cat. No. 28932257) by centrifugation at 3,500-4,000 x g at 4°C then, diluted with PBS pH 6 to achieve 4-fold and repeated until sample reached 200-fold. Dialysis was carried out in 4 L of PBS pH 6 overnight at 4°C using 7 kDa molecular weight cut-off dialysis tubing (Therm oFisher, Cat. No. 68799).
  • the desalting column was incubated with 0.5 M NaOH overnight and equilibrated with PBS pH 6. Volume of 15 mL of neutralized protein sample was loaded into the HiPrep 26/10 desalting column (GE Healthcare, Cat. No. 17- 5087-02) at 0.5 mL/min then, protein was eluted with 2 CV of PBS pH 6. Loading and elution steps were repeated until no neutralized protein sample from elution of affinity column is left. Fractions identified with protein from the visual output of the chromatogram (absorbance at 280 nm) were pooled together.
  • Sample was filter-sterilized using a NalgeneTM Rapid-FlowTM sterile disposable filter units 150 mL filter unit (Thermo Scientific, Cat. No. 565-0010).
  • the final protein sample was quantified by PierceTM bicinchoninic acid protein assay kit (Therm oFisher, Cat. No. 23227) and tested for endotoxin level with Endosafe® LAL reagent cartridges (Charles River Cat. No. PTS2005).
  • the final protein sample was analyzed on SDS-PAGE gels under reducing or non-reducing conditions.
  • Samples were prepared for SDS-PAGE analysis under reducing or non-reducing conditions with NuPAGETM LDS sample buffer (ThermoFisher Cat. No NP0007) with NuPAGETM sample reducing agent (ThermoFisher Cat. No. NP0004) or without reducing agent. Samples under reducing conditions were denatured by heating at 70 ° C for 10 minutes. Samples (16 ⁇ L) were loaded onto 3-8% Tris-Acetate mini-gels (1.5mm, 15 wells) alongside a BSA standard. Electrophoresis was conducted using a X-Cell SureLockTM mini-gel device at 125 volts for approximately 1 hour. Gels were stained using GelCodeTM staining reagent (Thermo Fisher, Cat. No. 24594). For western blots analysis, proteins were transferred to nitrocellulose membranes using the iBlotTM system (Thermo Fisher, Cat. No. GB301031) according to the manufacturer’s instructions.
  • NuPAGETM LDS sample buffer The
  • Detection of the His tag was carried out with the Anti-Penta His-HRP antibody. Briefly, membranes were blocked by incubation in 20 mL in Qiagen blocking buffer (Qiagen, Cat. No. 1018862) for 1 hour at room temperature with shaking, followed by incubation in 20 mL in Starting BlockingTM T20 (PBS) Blocking (Thermo Fisher, Cat. No. 37528) for 1 hour at room temperature with shaking. Membranes were washed three times for 10 minutes with IX TBS TweenTM-20. Membranes were incubated with Anti-Penta His-HRP (Qiagen, Cat. No. 1014992) previously diluted 1:2000 in blocking buffer for 1 hour at room temperature with shaking.
  • Membranes were washed three times for 10 minutes with IX TBS TweenTM-20. The signal was visualized using of Super SignalTM West Pico PLUS (ThermoFisher, Cat. No. 34080) according to the manufacturer’ s instructions. Images were recorded using the Azure Biosystem imaging system.
  • OCI-AML3 cells are acute myeloid leukemia cells of human origin that are used as target cells in PBMC-dependent cytotoxicity assays.
  • THP-1 is a monocytic cell line derived from acute monocytic leukemia patient. THP-1 cells are used as the target cells in the PBMC-dependent cytotoxicity assay.
  • NCI-H82, NCI-H69 and NCI-H510A are human small cell lung cancer (SCLC) cell lines that are used in SCLC xenograft tumor model in the immunodeficient mice.
  • SCLC small cell lung cancer
  • NCI-H82, NCI-H69 and NCI-H510A overexpress the dopamine receptor D2 and are used herein, amongst other things, as a models for D2 targeting studies.
  • NCI-H727 cells are human non-small cell lung cancer (NSCLC) cells that are used for NSCLC xenograft tumor model in immunodeficient mice model. D2 has been shown to be upregulated in the NCI-H727 cells.
  • NSCLC human non-small cell lung cancer
  • PANC1 is a human pancreatic cell line that is used for the xenograft tumor model in the immunodeficient micemodel.
  • human D2 presenting proteoliposomes were produced with ProteoLiposome BD kit from CellFree Science (CellFree Science, Cat. No. CFS-CPLE-BD) following the supplemented protocol.
  • a transcription reaction was set up by mixing required volumes of nuclease-free water, 5X Transcription buffer, NTP mix, RNase inhibitor, SP6 RNA polymerase and plasmid DNA, in a 1.5 mL tube with six-hour incubation at 37°C.
  • a mixture of mRNA mixture, feeding buffer, WEPRO7240, creatine kinase and asolectin liposome was prepared as instructed.
  • the translation reaction was set up by adding the translation reaction mixture to a slide- A-Lyzer Mini Dialysis device (Thermo Scientific, Cat. No. 69570) with 72-hour incubation at 15°C.
  • proteoliposomes were purified by washing with PBS and centrifuge at 15000 rpm, 4°C for 10 minutes. After repeating the washing steps for 3 times, the harvested proteoliposomes were resuspended in the appropriate amount of PBS and stored at -80°C. The binding of anti-D2 binding agents (e.g., Table 6) to human D2 presenting proteoliposomes ( Figure 1, Figure 25, Figure 26) was assessed by ELISA. Briefly, proteoliposomes containing the target protein or empty liposomes were coated on 96-well plates. Plates were covered and left at 4°C overnight. The next day, plates were washed once with PBS and blocked with blocking buffer for 1 hour at room temperature.
  • anti-D2 binding agents e.g., Table 6
  • Binding agents were tested at the indicated concentration, diluted in the blocking buffer, and incubate for 1 hour at 37°C. After incubation, plates were washed three times with washing buffer. Plates were incubated with anti- human-Fc-HRP (Sigma-Aldrich, Cat. No. AP113P ) diluted at 1:5000 for 1 hour at room temperature, then washed three times with PBS-T washing buffer. The signal was developed with SuperSignalTM ELISA Pico Chemiluminescent Substrate(Thermofisher, Cat. No. 37069). The plates were read on a SpectraMaxTM i3x Multi-Mode Microplate Reader (Molecular Devices).
  • HEK293 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 1% penicillin/streptomycin and 10% fetal bovine serum. Polyethylenimine (PEI) transfection reagent was used for all transfection.
  • DMEM Dulbecco's Modified Eagle Medium
  • PEI Polyethylenimine
  • HEK293 cells were cotransfected with hDR2 and one of the biosensors.
  • the total amount of transfected DNA was kept constant at 1 ⁇ g per mL of cell culture to be transfected.
  • the PEI to DNA ratio ( ⁇ g: ⁇ g) was fixed at 3:1. DNA and PEI were first diluted separately in 150 mM NaCl.
  • the volume of the diluent in each tube corresponds to 5% of the cell culture volume to be transfected.
  • BRET experiments were performed to detect the D2 downstream signaling in the agonist testing mode.
  • Culture medium was aspirated and replaced with 50 m ⁇ of Hank’s Balanced Salt Solution buffer from the 96-well plates.
  • 10 m ⁇ of 10 mM e- Coelenterazine Prolume Purple was added to each well for a final concentration of 1 mM for assays performed in HEK239 cells.
  • Dopamine was added to each well using the HP D300 digital dispenser as the positive control.
  • Dopamine was assayed at 16 concentrations with each biosensor.
  • Antibodies were added to each well manually (final concentration of 1 mM by well).
  • the anti-D2 binding agents were assayed at 8 concentrations with each biosensor in duplicates.
  • Cells were incubated with the dopamine at room temperature for 10 minutes and antibodies at room temperature for 60 minutes.
  • BRET signals were collected with a 0.4 sec integration time on a Synergy NEO plate reader.
  • KC013 The mechanism of action of KC013 was investigated in NCI-H69 cells in vitro , through the use of next-generation sequencing technology assessing global transcriptional profiles post treatment.
  • Suspension NCI-H69 cells were collected and resuspended at a concentration of 5xl0 6 cells/mL.
  • Ten million cells per 2mL of complete medium were transferred to the wells of a 6-well plate.
  • KC013 and negative control KC018 in which the VHH portion is replaced with the anti- 4HEM VHH set forth in SEQ ID NO: 114) were added to the appropriate wells at a final concentration of 1.0 mM.
  • Cells were returned to a 37°C, 5% C02 incubator and treated for 3 hours.
  • RNA integrity was assessed using an Agilent bioanalyzer. Libraries were prepared using the NEB mRNA stranded NEBNext Ultra II kit (NEB, Cat. No. E7645S), incorporating mRNA enrichment steps followed by Illumina library QC assessment. Samples were sequenced on a NovaSeq 6000 PEI 00 instrument (Illumina) at 25 million reads per sample.
  • RNA-Seq data revealed down-regulation of several cancer-associated pathways, including CREB, Wnt, and mTOR signaling pathways relative to the negative control (KC018) treated cells including NCI-H69 and NCI-H82 SCLC, and activation of p53 through multiple signaling pathways.
  • RNA-Seq data was validated by quantitative reverse transcriptase- PCR (qRT-PCR) using three different cell lines including NCI-H69 ( Figure 5A), NCI-H82 ( Figure 5B), and HEK-D2 ( Figure 5C). Briefly, suspension cells were grown in T175 flasks in complete medium. Cells were seeded in three 6-well plates at 5xl0 6 cells/mL per well and were treated with 1.0 mM KC013 or 1.0 mM of KC018 in triplicates for 3 hours and 6 hours. After the specified incubation period, replicates were scraped and transferred into 15 mL falcon tubes for each time point.
  • qRT-PCR quantitative reverse transcriptase- PCR
  • RNA was extracted using the Quick- RNA Miniprep Plus kit (Cedarlane, Cat. No. R1057), according to the manufacturer’s instructions. The amount of RNA recovered for each sample was quantified by measuring absorbance at 260 and 280 nm using NanoPhotometer. 1 pg of RNA was used for reverse transcription with the iScriptTM Reverse Transcription Supermix, according to manufacturer’s instructions. The resulting cDNAs were then diluted 1 :20 using ddH20 containing 40 ng/mL glycogen.
  • Figure 4 represents the downregulated signaling pathways and protein classes from the PANTHER analysis of the RNAseq result.
  • the top downregulated signaling pathways include Wnt pathway, Gonadotropin-releasing hormone (GnRH) pathway and the Cadherin signaling pathways (Figure 4A).
  • the most downregulated protein classes by PANTHER analysis are gene-specific transcriptional regulators ( Figure 4B).
  • Wnt pathway and Cadherin signaling pathway has been suggested to played important roles in tumor cell survival, proliferation, tumor formation, and progression.
  • Aberrant Wnt signaling pathway has been shown to play a key role in the initiation of many cancer cells by regulating Cancer Stem Cells (CSCs). Downregulation of these pathways and transcriptional regulators suggests the anti -tumor mechanism of KC013.
  • mice CB-17 Fox Chase SCID mice (6-8 weeks old, female), purchased from University Health Network (UHN, Toronto, ON) were used for the PK studies. Mice were housed in a pathogen-free environment at the animal facility in UHN. The animal work was conducted according to the guidelines of the Canadian Council on Animal Care (CCAC) and the Animal Use Protocol approved by the Animal Care Committee at UHN. In brief, mice were divided into 2 experimental groups (6 mice/group), and each group of the mice received a 30 mg/kg single dose of Trastuzumab (UHN pharmacy store) or KC013 by either intravenous injection (Figure 6A) or intraperitoneal injection ( Figure 6B).
  • CCAC Canadian Council on Animal Care
  • mice serum Antibodies in the mice serum were quantified by quantitative ELISA ( Figure 6).
  • mouse anti-human IgG antibody Bio-rad, Cat. No. MCA878G, using 1/200 dilution
  • plate was washed three times and blocked with 2% BSA for 1 hour at room temperature.
  • standard Bio-rad, Cat. No. MCA6092
  • quality control QC
  • each serum sample were diluted in the washing buffer containing 1% mouse serum. 100 m ⁇ of STD, QC, and diluted serum sample were added into the 96-well plates and incubated for 2 hours at room temperature.
  • mice (6-8 weeks old, female) were purchased either from Charles River Laboratories (St. Constant, QC) or from UHN (Toronto, ON). The animal husbandry and the guidelines of animal work are the same as those described above.
  • NCI-H510A Figure 7C, Figure 8
  • NCI-H727 Figure 7A, Figure 8
  • PANC1 Figure 8
  • NCI-H69 Figure 7B, Figure 8
  • tumor cells 8 million cells/mouse for NCI- 11510 A, 6 million/mouse forNCI-H727, 5 million/mouse for PANC1, or 3 million/mouse for NCI- 1169 in DPBS were injected subcutaneously (s.c.) into the right flank of mice.
  • mice inoculated with each cell line were randomly divided into 2 experimental groups (10 or 5 mice/group), and each group of mice received 16 mg/kg ip. either KC018 (negative control) or KC013, twice weekly, for a total of eight weeks. Tumor volumes were measured using vernier calipers and the mice were weighed one or two times weekly. Tumor volume was calculated using the formula: 1 ⁇ 2 (Length c Width 2 ). For calculation of percentage tumor growth inhibition (TGI), KC013 treated group was compared with its respective negative control. TGI was calculated by the following formula:
  • TV day z represents the tumor volume of an individual animal at a defined study day (day z) and TV day x represents the tumor volume of an individual animal at the staging day (day x).
  • KC013 showed 49% tumor growth inhibition in the NCI-H727 tumor prevention model (Figure 7A), 46% tumor growth inhibition in the NCI-H69 tumor prevention model ( Figure 7B) and 77% tumor growth inhibition in the NCI-H510A tumor prevention model ( Figure 7C) in comparison with isotype control.
  • KC013, KC012, and KC014 demonstrated a universal tumor growth inhibition in all of the tumor prevention SCLC tumor models, with KC013 obtaining the best in vivo efficacy than other anti-D2 binding agents.
  • the in vivo efficacy achieved in SCLC tumor models may be relevant with the specific Gaz signals in the tumor cells.
  • the in vivo efficacy is also explained by the downregulated signaling pathways which are important for tumor progression.
  • Example 4- In vitro and in vivo testing of binding agents comprising anti-PDl and anti-CD47 antigen binding domain(s)
  • ELISA binding assays The binding of binding agents comprising anti-PD-1 and-CD47 antigen binding domain to recombinant human or cynomolgous PD-1 (Cedarlane, Cat. No. HPLC-10377-H08H-100) or recombinant human or cynomolgous CD47 (Cedarlane, Cat. No. 12283-H08H-200 and 90869- COSH) was assessed by ELISA ( Figure 9A, Figure 9B, Figure 9C, Figure 9D, Figure 22, Figure 23). Pembrolizumab was used as a positive control in PD1 binding assays. The monoclonal anti- CD47 antibody (clone B6H12 )was used as a positive control in CD47 binding assays (Biolegend, Cat. No. 401401).
  • recombinant proteins were coated on 96-well plates. Plates were covered and left at 4°C overnight. The next day, plates were washed once with PBS and blocked with blocking buffer for 1 hour at room temperature. Binding agents were tested at the indicated concentration, diluted in the blocking buffer, and incubated for 1 hour at 37°C. After incubation, plates were washed three times with washing buffer. Plates were incubated with anti-human-Fc-HRP (Sigma- Aldrich, Cat. No. AP113P) diluted at 1:5000 for 1 hour at room temperature, then washed three times with PBS-T washing buffer.
  • anti-human-Fc-HRP Sigma- Aldrich, Cat. No. AP113P
  • the signal was developed with SuperSignalTM ELISA Pico Chemiluminescent Substrate (Thermofisher, Cat. No. 37069).
  • the plates were read on a SpectraMaxTM i3x Multi-Mode Microplate Reader (Molecular Devices).
  • the anti -PD 1 binding agent KC009 efficiently binds to human, cynomolgus monkey, and rat recombinant PD1 proteins.
  • the cross-species binding activity of KC009 implies the feasibility of using cynomolgus monkey and rat as the toxicity model for KC009.
  • KC036 The binding of KC036 was compared with Pembrolizumab. Both KC036 and Pembrolizumab were diluted 1/5, starting from 500 nM. As illustrated in Figure 9B, KC036 binds similarly to Pembrolizumab by ELISA. The negative control KC036 did not bind to the PD-1 recombinant protein.
  • KC015 The binding of KC015 was compared with the anti-CD47 antibody B6H12 (ThermoFisher, Cat. No. 14-0479-82). Both KC015 and B6H12 antibodies were diluted 1/5, starting from 50 nM. As illustrated in Figure 9C, KC015 showed higher binding affinity than clone B6H12 by ELISA. The negative control KC016 did not bind to the CD47 recombinant protein.
  • the anti-CD47 binding agent efficiently binds to human and cynomolgus monkey CD47 recombinant protein, whereas the negative control showed no binding to both of the CD47 recombinant protein.
  • red blood cell (RBC) preparation and staining fresh blood was transferred to a 15 mL conical bottom polypropylene tube and mixed with the PBS washing buffer (PBS + 2% heat- inactivated FBS). Tubes were centrifuged at 800g for 10 minutes at room temperature with the brake off. Red blood cells were collected from the bottom of the tube, resuspended into the PBS washing buffer (PBS + 2% heat-inactivated FBS), and counted the cell number before staining with the binding agents.
  • PBS washing buffer PBS + 2% heat- inactivated FBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/CA2022/050442 2021-03-31 2022-03-25 Binding agents targeting tumors and/or immune cells Ceased WO2022204793A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA3174330A CA3174330A1 (en) 2021-03-31 2022-03-25 Binding agents targeting tumors and/or immune cells
EP22778240.6A EP4314076A4 (en) 2021-03-31 2022-03-25 BINDING AGENTS TARGETING TUMOR AND/OR IMMUNE CELLS
US18/283,579 US20240166739A1 (en) 2021-03-31 2022-03-25 Binding agents targeting tumors and/or immune cells
CN202280025997.9A CN117157322A (zh) 2021-03-31 2022-03-25 靶向肿瘤和/或免疫细胞的结合剂
JP2023560694A JP2024512741A (ja) 2021-03-31 2022-03-25 腫瘍及び/又は免疫細胞を標的化する結合剤
ARP220100796A AR125264A1 (es) 2021-03-31 2022-03-31 Agentes aglutnantes dirigidos a tumores y/o células inmunitarias
TW111112543A TW202304993A (zh) 2021-03-31 2022-03-31 靶向腫瘤及/或免疫細胞之結合劑

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163168606P 2021-03-31 2021-03-31
US63/168,606 2021-03-31
US202163249784P 2021-09-29 2021-09-29
US63/249,784 2021-09-29
US202263301305P 2022-01-20 2022-01-20
US63/301,305 2022-01-20

Publications (1)

Publication Number Publication Date
WO2022204793A1 true WO2022204793A1 (en) 2022-10-06

Family

ID=83455216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2022/050442 Ceased WO2022204793A1 (en) 2021-03-31 2022-03-25 Binding agents targeting tumors and/or immune cells

Country Status (7)

Country Link
US (1) US20240166739A1 (cg-RX-API-DMAC7.html)
EP (1) EP4314076A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024512741A (cg-RX-API-DMAC7.html)
AR (1) AR125264A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174330A1 (cg-RX-API-DMAC7.html)
TW (1) TW202304993A (cg-RX-API-DMAC7.html)
WO (1) WO2022204793A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024073842A1 (en) * 2022-10-03 2024-04-11 Kisoji Biotechnology Inc. Multispecific binding agents targeting dopamine receptor d2 and methods of use thereof
WO2024086928A1 (en) * 2022-10-25 2024-05-02 Kisoji Biotechnology Inc. Binding agents targeting cd36-expressing tumor cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035092A2 (en) * 2005-09-23 2007-03-29 Academisch Ziekenhuis Leiden Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates
WO2011051327A2 (en) * 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2016124768A1 (en) * 2015-02-05 2016-08-11 Janssen Vaccines & Prevention B.V. Binding molecules directed against influenza hemagglutinin and uses thereof
US20180222966A1 (en) * 2013-04-29 2018-08-09 Agrosavfe N.V. Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody
WO2021004480A1 (zh) * 2019-07-08 2021-01-14 南京金斯瑞生物科技有限公司 抗cd47/抗pd-1双特异抗体及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2747644C (en) * 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
US10874685B2 (en) * 2014-04-17 2020-12-29 The Royal Institution For The Advancement Of Learning/Mcgill University Pancreatic cancer therapy and diagnosis
CA3065999A1 (en) * 2017-05-24 2018-11-29 Nanosomix, Inc. Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders
WO2019179434A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/cd47 antibody molecules

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035092A2 (en) * 2005-09-23 2007-03-29 Academisch Ziekenhuis Leiden Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates
WO2011051327A2 (en) * 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
US20180222966A1 (en) * 2013-04-29 2018-08-09 Agrosavfe N.V. Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody
WO2016124768A1 (en) * 2015-02-05 2016-08-11 Janssen Vaccines & Prevention B.V. Binding molecules directed against influenza hemagglutinin and uses thereof
WO2021004480A1 (zh) * 2019-07-08 2021-01-14 南京金斯瑞生物科技有限公司 抗cd47/抗pd-1双特异抗体及其制备方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KHAN ZAFAR U., MRZLJAK LADISLAV, GUTIERREZ ANTONIA, DE LA CALLE ADELAIDA, GOLDMAN-RAKIC PATRICIA S.: "Prominence of the dopamine D2 short isoform in dopaminergic pathways", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 95, no. 13, 23 June 1998 (1998-06-23), pages 7731 - 7736, XP055976039, ISSN: 0027-8424, DOI: 10.1073/pnas.95.13.7731 *
See also references of EP4314076A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024073842A1 (en) * 2022-10-03 2024-04-11 Kisoji Biotechnology Inc. Multispecific binding agents targeting dopamine receptor d2 and methods of use thereof
WO2024086928A1 (en) * 2022-10-25 2024-05-02 Kisoji Biotechnology Inc. Binding agents targeting cd36-expressing tumor cells

Also Published As

Publication number Publication date
US20240166739A1 (en) 2024-05-23
CA3174330A1 (en) 2022-09-30
EP4314076A1 (en) 2024-02-07
JP2024512741A (ja) 2024-03-19
AR125264A1 (es) 2023-06-28
TW202304993A (zh) 2023-02-01
EP4314076A4 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
US20230322924A1 (en) Anti-cd3 antibodies and uses thereof
TWI830761B (zh) 針對cldn18.2和cd3之抗體構建體
TWI907375B (zh) 多肽、蛋白質複合物及其製造方法
TWI812637B (zh) 限制性條件性活化之結合蛋白
US10253104B2 (en) Bispecific antibodies against CD3ϵ and BCMA
US12076384B2 (en) Bispecific EGFR/CD16 antigen-binding protein
JP2025163013A (ja) 拘束され、条件的に活性化された結合タンパク質
KR20230048146A (ko) 제약된, 조건부 활성화 결합 단백질들
US20240166739A1 (en) Binding agents targeting tumors and/or immune cells
CN117157322A (zh) 靶向肿瘤和/或免疫细胞的结合剂
US20250313638A1 (en) Multispecific binding agents targeting dopamine receptor d2 and methods of use thereof
US20250326857A1 (en) Binding agents targeting cd36-expressing tumor cells
US20240400697A1 (en) Humanized anti-egfr viii antibodies and antigen-binding fragments thereof
HK40126767A (en) Anti-cd3 antibodies and uses thereof
HK1218299B (en) Bispecific antibodies against cd3epsilon and bcma

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3174330

Country of ref document: CA

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22778240

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023560694

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2022778240

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2022778240

Country of ref document: EP

Effective date: 20231031

NENP Non-entry into the national phase

Ref country code: DE